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Women with preeclampsia have enhanced vascular reactivity to Angiotensin II 
(Ang II) and extensive vascular infiltration of neutrophils. The primary mechanism to 
enhance vessel reactivity is RhoA kinase that phosphorylates MYPT1 to inhibit myosin 
light chain (MLC) phosphatase. Therefore, MLCs remain phosphorylated and increase 
sensitivity to calcium. Neutrophils release reactive oxygen species (ROS), which can 
activate this pathway, so we hypothesized that neutrophils would enhance vessel 
reactivity to Ang II. Omental vessels from normal pregnant women were used to study 
vascular reactivity. Ang II dose response (0.001-10µM) was significantly enhanced with 
perfusion of neutrophils (<2000/mm3, activated with IL-8) or ROS. Addition of 
 xviii 
superoxide dismutase (SOD)/Catalase to quench ROS or 3µM Y-27632, a specific RhoA 
kinase inhibitor, blocked enhancement. Vascular smooth muscle expression of pMYPT1 
and pMLC in cell culture was significantly increased by neutrophils or ROS. The 
increase was prevented by Y-27632. RhoA kinase activity assay showed a 3-fold increase 
in RhoA kinase activity in omental vessels treated with ROS. Similarly, ROS also 
enhanced vessel reactivity to another vasoconstrictor, norepinephrine, via RhoA kinase. 
In preeclamptic women, increased neutrophil infiltration is associated with increased 
vascular expression and production of matrix metalloproteinase-1 (MMP-1). MMP-1 
activates protease activated receptor-1 (PAR-1), which could cause endothelial 
endothelin-1 release, so we considered a novel hypothesis that MMP-1 might cause 
vasoconstriction and enhance vessel reactivity to Ang II via PAR-1. Omental vessels 
perfused with activated MMP-1 (0.025-25ng/ml) showed dose-dependent 
vasoconstriction. Perfusion of activated MMP-1 (2.5ng/ml) significantly enhanced dose 
response to angiotensin II. MMP-1 mediated vasoconstriction and enhanced vessel 
reactivity to Ang II was abolished by co-perfusion of 10µM SCH-79797, a specific PAR-
1 blocker, and by 5µM BQ-123, a specific endothelin-1 type A receptor blocker. These 
data are the first to show that activated neutrophils enhance vascular reactivity to Ang II 
via ROS and the RhoA kinase pathway. They are also the first to show that MMP-1 
induces vasoconstriction and enhances vessel reactivity to Ang II. Thus, vascular 
neutrophil infiltration leading to ROS and MMP-1 generation could be an important 
mechanism for hypertension in preeclampsia. 
       
 
 
CHAPTER 1 
 
GENERAL INTRODUCTION 
 
A. Preeclampsia  
Preeclampsia is a hypertensive disorder of pregnancy, which results in 
considerable maternal and fetal morbidity and mortality. Sixteen percent of all pregnancy 
related deaths in the US from 1991-1999 were the result of pregnancy related 
hypertension1. The incidence of preeclampsia is 7.6% in nulliparous pregnancies and 
3.3% of all nulliparous women experience severe disease2. Preeclampsia is a disorder 
more common at both extremes of age and also in the first pregnancy. Diastolic blood 
pressure above 95 mmHg significantly increases fetal death rate. African American 
women are 3 times more likely to die from preeclampsia as compared to Caucasian 
women3. In developing nations the perinatal mortality is more than six times higher in 
infants of preeclamptic women as compared to infants of normal pregnant women4 
(WHO defines perinatal mortality as death of the fetus between 22 weeks of gestation and 
seventh day of life and includes fetal deaths during childbirth). Minimum defining 
criteria for preeclampsia are BP >140/90 mm Hg after 20 weeks’ gestation in a 
previously known normotensive woman along with proteinuria of 300 mg/day or more5. 
Complications include HELLP (hemolysis, elevated liver enzyme levels, and a low 
platelet count) syndrome, eclampsia characterized by seizures with or without cerebral 
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hemorrhage and risk of maternal death. Currently, the only definitive treatment is 
delivery of the fetus and removal of the placenta. Since preeclampsia is usually seen early 
in pregnancy (< 34 weeks of gestation), delivery of the fetus results in a high incidence of 
pre-term infants. Pre-term infants are often low birth weight babies with high rates of 
mortality and morbidity. 
 
Pathophysiology of Preeclampsia: Preeclampsia is a topic that has been vastly studied 
and yet a lot remains to be determined. A number of theories have been proposed to 
explain pathogenesis of preeclampsia and I will attempt to discuss the relevant literature 
to date. 
 
1. Endothelial Dysfunction: The role of endothelium in the pathogenesis of preeclampsia 
is complex and involves a number of factors that ultimately lead to inappropriate 
endothelial cell activation, also known as endothelial cell dysfunction6. Endothelial 
activation results in increased production of vasoconstrictors and pro-coagulants like Von 
Willebrand’s factor (vWF)7, endothelin-1 (ET-1)8, thromboxane, prostaglandin-F2α 
(PGF2α)9 and platelet derived growth factor (PDGF) along with a decrease in production 
of vasodilators10 and anti-coagulants like prostacyclins11, 12, nitric oxide (NO)13 and 
endothelium derived hyperpolarizing factor. This imbalance results in a vasoconstricted 
state that causes hypertension and reduced capacity of the vascular system in 
preeclampsia. The mitogenic activity of PDGF results in vessel hyperplasia and 
thickening14, akin to atherosclerosis. Moreover, placental factors in preeclampsia disrupt 
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endothelial junction molecules and increase endothelial permeability15, which can explain 
the edema and proteinuria in preeclampsia16. Endothelial activation also releases 
chymase, interleukin-8 (IL-8) and P-selectin and up-regulates expression of vascular cell 
adhesion molecule-1 (VCAM-1)17. IL-8 is a potent chemo-attractant for neutrophils, 
while VCAM-1 and P-selectin18 promote attachment and infiltration of immune cells 
across the endothelium, thus promoting neutrophil infiltration and vascular inflammation 
in preeclampsia. Endothelial release of chymase increases local levels of angiotensin II 
(Ang II) by catalyzing conversion of Angiotensin I to Ang II19. 
 
2. Oxidative stress: Oxidative stress is a state characterized by an excess of oxidants as 
compared to anti-oxidants. The major oxidants are free radicals and reactive oxygen 
species (ROS). Free radical is defined as a molecule containing one or more unpaired 
electrons and capable of independent existence. ROS is a collective term for oxygen 
derived free radicals as well as non-radical derivatives of oxygen such as hydrogen 
peroxide (H2O2)20. Antioxidants are compounds that can react with ROS and free radicals 
to convert them into non-oxidizing molecules. Major cellular antioxidant enzymes are 
catalase, glutathione peroxidase and superoxide dismutase (SOD). SOD dismutates the 
superoxide anion (O2-) to H2O2 and oxygen21. Activity of SOD is significantly decreased 
in preeclampsia22, 23. Catalase and glutathione peroxidase catalyse the conversion of H2O2 
to water and oxygen21. Other known antioxidants are Vitamins A, E and C, as well as uric 
acid, transferrin, ceruloplasmin and quinines. In preeclampsia, there is a reduction in the 
total antioxidant capacity of the serum24 along with an increase in superoxide production. 
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In preeclampsia, levels of nitric oxide (NO) metabolites and endothelial nitric oxide 
synthase (eNOS) are elevated25. Although this would seem to be protective as NO is a 
vasodilator, overproduction of O2- by neutrophils26 results in endothelial cell injury 
because endothelial NO reacts with O2- to form peroxynitrite (ONOO-)27. Peroxynitrite 
levels are elevated in preeclampsia28 and can induce eNOS uncoupling which causes the 
NO synthesizing enzyme to produce superoxide29. Peroxynitrite thus interferes with NO 
dependent relaxation and can also decompose into the hydroxyl ion (OH-)20. Hydroxyl 
ion is a potent oxidizing agent that can directly impair cellular function and mediate the 
vascular response in preeclampsia20. Levels of 8-epi-PGF2α, a marker of lipid 
peroxidation, are increased in preeclamptic women30. Also abnormal mitochondria in 
preeclamptic placentas31 are indicative of oxidative stress at the cellular level32, 33. 
Oxidative stress and lipid peroxidation of the endothelial cell membrane alter its fluidity 
and result in an increase in endothelial cell junction permeability34. 
 
3. Thromboxane/Prostacyclin Imbalance: In 1985, Walsh first demonstrated the presence 
of thromboxane/prostacyclin imbalance35. Within the placenta, lipid peroxides are formed 
from the interaction of polyunsaturated fatty acids with free radicals in normal 
pregnancy36. In placentas from preeclamptic pregnancies there is significantly more lipid 
peroxide formation37, 38. Lipid peroxides are known to stimulate cyclooxygenase 
production of prostaglandins and thromboxanes39. Lipid peroxides also inhibit the 
prostacyclin synthase enzyme40, 41. Further evidence comes from studies showing 
decreased plasma concentrations and urinary excretion of prostacyclin (PGI2) metabolites 
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by preeclamptic women11. Thus, enhanced lipid peroxide formation in preeclamptic 
placental tissue results in thromboxane/prostacyclin imbalance favoring thromboxane42. 
Thromboxane A2 is a potent vasoconstrictor43 while PGI2 is a potent vasodilator and 
inhibitor of platelet aggregation43, 44. Thus, the thromboxane/prostacyclin imbalance 
induces placental as well as systemic vasoconstriction and can explain the placental 
hypoperfusion and intra-uterine growth restriction seen in preeclampsia. 
 
4. Vasomotor tone and reduced blood supply: Lipid peroxides have been shown to cause 
vasoconstriction in the systemic vasculature45 and could explain maternal hypertension in 
preeclampsia. Lipid peroxides also increase calcium influx within the cells45. The 
thromboxane/prostacyclin imbalance and increased sensitivity to usual pressors46 in 
preeclampsia could also partially explain the maternal hypertension and rise in basal tone. 
In preeclampsia, plasma volume is reduced, however levels of atrial natriuretic peptide 
(ANP) are elevated47 and plasma renin activity is low48. This suggests that the vasculature 
is overfull even though there is low circulating plasma volume49 and that there is an even 
greater reduction in the capacity of the vasculature than the reduction of plasma volume. 
This is explained by the combined result of vasoconstriction and the formation of 
microthrombi in the vasculature secondary to the pro-coagulant state in preeclampsia. 
The end result is hypertension and reduced blood supply to all organs.  
 
5. Abnormal placentation: Evidence for a role of abnormal placentation in the 
pathogenesis of preeclampsia is evident from a case report describing a woman with an 
 6
abdominal pregnancy and retained placenta. She remained preeclamptic for many months 
until the placenta was absorbed50. Thus the presence of a placenta is a prerequisite to the 
development of preeclampsia but obviously not sufficient cause of preeclampsia in itself. 
It has been suggested that the underlying cause of preeclampsia is reduced placental 
perfusion. During normal pregnancy, the spiral arterioles of the non-pregnant state 
undergo considerable vascular remodeling to supply the inter-villous space of the 
developing placenta. These small muscular arteries increase considerably in diameter and 
lose their muscle and inner elastic lamina51. During the first ten weeks of gestation high 
metabolic requirements of the fetus result in a hypoxic stimulus within the placenta 
which leads to the release of vascular endothelial growth factor (VEGF) from decidual 
macrophages. VEGF is an angiogenic factor that acts on the VEGF receptors on 
cytotrophoblasts and transforms them into endothelial-like cells. The lumen and vessel 
walls of the spiral arteries are invaded by extracellular trophoblast. This trophoblast 
invasion extends into the inner third of the myometrium and is completed by 20 weeks of 
gestation52. These changes do not proceed in a normal manner in preeclamptic 
pregnancies. In preeclampsia, these changes may be absent or restricted to only the 
superficial decidual segment of the spiral arteries51. This leads to decreased placental 
perfusion in preeclampsia. 
 
B. Neutrophils in Preeclampsia: 
Neutrophils are the most abundant white blood cells (WBC) in the circulation 
(65% of all WBC). They are the first line of defense against bacterial and fungal 
 7
infections to be recruited to sites of infection and they contain an impressive armory of 
cytotoxic mechanisms capable of killing a wide range of microbial organisms. 
Inappropriate activation of these cytotoxic mechanisms can lead to tissue damage. 
Therefore, the process of neutrophil emigration and activation is controlled at several 
stages53. In preeclampsia all these controls are overcome to result in neutrophil 
infiltration and activation in the absence of any underlying infection. 
Neutrophil numbers are increased up to 2.5 fold in normal pregnancy65. Luries et 
al reported further increase neutrophil numbers in preeclampsia as compared to normal 
pregnancy54. Greer et al were the first to present evidence for neutrophil activation in 
preeclampsia by the demonstration of elevated levels of neutrophil elastase, a marker of 
neutrophil activation, in plasma from preeclamptic women as compared to that from 
normal pregnant women55. Increased neutrophil elastase levels in preeclamptic women 
are independent of the absolute neutrophil count 56 which is the number of neutrophils per 
mm3 of whole blood. The substrates for neutrophil elastase are elastin, collagen, 
fibrinogen and proteoglycans56. Thus, along with other proteases it can cause vascular 
basement membrane damage and facilitate tissue infiltration of neutrophils. Vascular 
basement membrane damage could also contribute to the edema and proteinuria of 
preeclampsia. 
Neutrophil activation in preeclampsia is confined to the maternal circulation57. 
Additional evidence of neutrophil activation in preeclampsia came with demonstration of 
increased neutrophil expression of CD11b; a surface marker of neutrophil activation58. 
Also, neutrophils from preeclamptic women generated significantly increased levels of 
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ROS and reduced expression of L-selectin (CD62L)59, 60.  Recently, it was shown that 
neutrophils isolated from preeclamptic women generated significantly more superoxide 
than the neutrophils from normal pregnant women but did not differ significantly from 
neutrophils of non-pregnant women61. Also, the exposure to plasma from normal 
pregnant women inhibited superoxide production by non-pregnant neutrophils but did not 
affect superoxide production by preeclamptic neutrophils61, suggesting altered response 
of preeclamptic neutrophils to the protective anti-oxidant factors in plasma from normal 
pregnant women. 
Neutrophil gelatinase associated lipocalin (NGAL), a matrix glycoprotein of 
human neutrophil granules62, is strongly induced during neutrophil activation and 
inflammation63. Elevated levels of NGAL have been reported in women predestined to 
develop preeclampsia. NGAL levels showed a strong positive correlation with 
development of hypertension and proteinuria64; providing additional evidence to support 
the role of neutrophils in the pathogenesis of preeclampsia. Luppi et al reported 4.5-fold 
increase in the DNA binding activity of NF-κB in preeclamptic women as compared to 
normal pregnant women not in labor60. Even when compared to normal women in labor, 
there was a 3.5 and 2 fold increase in the nuclear translocation of NF-κB p50 and p65 
subunits, respectively. Nuclear translocation of NF-κB subunits initiates transcription of 
genes involved in regulation of inflammation65 
 
Source of activation of neutrophils: 
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i) Placenta  
 
Neutrophil activation by placental lipid peroxides was first suggested by Walsh in 
199436. The primary source of lipid peroxides in the placenta is the trophoblast layer of 
cells that bathe the maternal blood38. Thus the neutrophils circulating within the 
intervillous space are exposed to high levels of lipid peroxides 36 (Fig 1). Lipid 
peroxidation of leukocytes results in sustained activation66. Lipid peroxide production is 
significantly higher in placentas of preeclamptic women38.  Placenta is also a rich source 
of linoleic acid67, which is known to stimulate placental release of thromboxane. 
Thromboxane in turn stimulates TNFα and superoxide production by neutrophils68. 
Placental secretion of TNFα can also directly activate neutrophils circulating within the 
intervillous space. Placental mRNA expression and synthesis of TNFα is significantly 
higher in preeclamptic placentas69. Increased placental production and circulation of 
synctiotrophoblast microvillus membrane micro-particles (STMB), known to activate 
neutrophils via increased expression of CD11b and superoxide production, has been 
reported in preeclampsia70.  
Brinkmann et al reported that neutrophil activation by IL-8, LPS or phorbol 
myristate acetate resulted in the release of granule proteins and chromatin which formed a 
web of extracellular fibril matrix called neutrophil extracellular traps (NET)71. NET is 
composed of a chromatin DNA backbone with histones, granular peptides and enzymes 
like elastase and myeloperoxidase71, 72. Recently it was reported that placentally derived 
STMB and soluble factors like IL-8 efficiently activate neutrophils to generate NET’s 
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rich in DNA, elastase and histones, which trap STMB particles73. Preeclamptic placentae 
showed significantly increased numbers of NET’s within the intervillous space73. NET’s 
are also released within the maternal circulation and may explain the increased 
concentrations of maternal cell free DNA in preeclamptic women reported by Zhong74. 
They also cause physical obstruction to blood flow within the placenta and contribute to 
placental hypo-perfusion and IUGR. 
 
ii) Cytokines and cell adhesion molecules  
 
Neutrophils are also activated by TNFα. Increased levels of circulating VCAM-1 
and intercellular cell adhesion molecule-1 (ICAM-1)75-77 lead to increased neutrophil 
adherence to the endothelium78. TNFα enhances neutrophil superoxide production79 and 
levels of TNFα and its soluble receptor are elevated in plasma and amniotic fluid of 
preeclamptic women80, 81. Elevated levels of IL-6 in preeclampsia60, 80, 82 are also 
associated with increased circulating ICAM-1 and increased endothelial expression of 
VCAM and E-selectin83. Increased VCAM, E-selectin and ICAM-1 facilitate neutrophil 
adherence to the endothelium84, 85. IL-186 and IL-8 are potent activators of neutrophils87 
while IL-6 and ET-1 prime neutrophils for superoxide production88. 
 
iii) Small dense LDL and VLDL 
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In preeclampsia concentrations of small dense LDL and VLDL-1 are increased. 
Small dense LDL is readily oxidized. Oxidized LDL induces VCAM-1 expression on 
endothelial cells89 and CD11b/CD18 expression on neutrophils promoting neutrophil 
adhesion to the endothelium90.  
 
iv) ET-1 
 
Levels of ET-1 are increased in preeclampsia. ET-1 is involved in neutrophil 
superoxide production91, intracellular calcium release92 and neutrophil aggregation93 and 
adhesion94.  
 
Activated neutrophils in turn release TNFα, IL-6 and superoxide, which can then 
generate feed forward cycles of neutrophil activation. 
 
Evidence of neutrophil infiltration of systemic vasculature in preeclampsia:  
Immunohistochemistry has shown the presence of significantly increased numbers 
of neutrophils flattened onto the endothelium, infiltrating within the intima and within 
muscular layers of resistance size arteries of the systemic circulation in preeclamptic 
women as compared to that in the vasculature of normal pregnant women95, 96. Using the 
CD66b marker for granulocytes (96% of granulocytes are neutrophils), it has been shown 
that there is significantly greater neutrophil infiltration within the systemic vasculature in 
preeclamptic women as compared to normal pregnant women96, 97. Furthermore, 
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activation of the neutrophils infiltrating the vasculature was demonstrated with markers 
for activated NF-κB, COX-2 expression95, IL-8 and ICAM-196. Of these, IL-8 is a potent 
chemo-attractant for neutrophils. Increased expression of IL-8 in the VSMC’s establishes 
a concentration gradient of IL-8 across the endothelium, promoting neutrophil emigration 
across the endothelium96. Increased endothelial ICAM-1 expression promotes neutrophil 
adhesion and activation85. Neutrophil activation and release of ROS along with cytokines 
like TNFα and IL-1 can induce NF-κB activity and trigger a cascade of inflammatory 
reactions65. NF-κB activation triggers up-regulation of genes encoding pro-inflammatory 
cytokines, adhesion molecules, chemokines and enzymes like COX-298 causing 
inflammation.  
In the presence of inflammation, endothelial cells express antigens that recruit, 
sequester and transfer circulating cells to the site of inflammation. This is a crucial and 
necessary role of endothelial cells to effect the neutrophil emigration. In preeclampsia, 
there is increased expression and circulating concentrations of VCAM-1, ICAM-199 and 
P-selectin100. Endothelial activation by placental derived factors results in up-regulation 
of adhesion molecules, such as P-selectin and E-selectin101. Both are involved in the early 
phases (capture and rolling) of neutrophil/endothelial and platelet/endothelial interaction 
and adhesion. The increased ICAM-1 expression on endothelial cells along with 
increased CD11b and IL-8 receptor expression on neutrophils promotes neutrophil 
emigration in preeclampsia. 
In preeclampsia inappropriate endothelial activation or endothelial dysfunction 
results in translocation of vWF and fibronectin from the abluminal surface to the luminal 
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surface of endothelial cells. vWF and fibronectin are both pro-coagulant molecules with 
adhesive properties and when on the luminal surface they interact with platelets and 
leukocytes in the circulation to promote neutrophil emigration102.  
Neutrophil degranulation on endothelial cells results in degradation of fibronectin 
and spread of fibronectin fragments on endothelial cells. Degraded fibronectin stimulates 
the neutrophils and can induce further fibronectin breakdown setting up a feed forward 
inflammatory loop. Loss of the fibrillary architecture of fibronectin on endothelial cells is 
a marker of endothelial injury103.  Circulating levels of fibronectin are elevated in 
preeclampsia104 suggesting increased neutrophil degranulation and fibronectin 
degradation in preeclampsia. Neutrophil degranulation at the endothelial surface leads to 
endothelial damage and dysfunction. 
 
Neutrophils and oxidative stress:  
Neutrophil activation and degranulation is capable of generating considerable 
oxidative stress as activated neutrophils make large quantities of superoxide via the 
NADPH oxidase enzyme system105. Also, 1-4% of oxygen used in the mitochondrial 
electron transport pathway is converted to superoxide106. Wright et al first provided direct 
evidence of nitric oxide generation by human neutrophils. In neutrophils, nitric oxide is 
produced by oxidation of one of the terminal nitrogens of arginine via calcium-dependent 
inducible nitric oxide synthase (iNOS-Type II)107, 108. The interactions and effects of 
neutrophil generation of reactive oxygen species and reactive nitrogen intermediates 
relevant to preeclampsia are illustrated in Fig 2. Hydrogen peroxide (H2O2) can easily 
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pass across cell membranes109. However, within the neutrophils in the presence of 
myeloperoxidase, which is abundant in primary azurophilic granules of neutrophils110, 111, 
H2O2 primarily reacts with halides like Cl- to form hypochlorous acid (HOCl). HOCl is 
known to inactivate sulfhydryl dependent transporter systems within cell membranes112. 
Peroxynitrite is a potent and reactive oxidant113  that can damage endothelial cells 
directly114, 115 and impair vascular permeability116. In the presence of H2O2, the half life 
of ONOO- is prolonged117. Transition metals catalyze formation of hydroxyl ion (OH-) 
and nitronium ion (NO2+) from ONOO-. Hydroxyl ion is a highly reactive oxidant that 
can directly impair cellular function20.  
 
NET’s generate oxidative stress in the placenta by interfering with blood flow 
through intervillous space increasing the degree of hypoxia73. Hypoxia promotes 
placental release of inflammatory cytokines like IL-6 and IL-8. These cytokines are 
known to stimulate NET production by neutrophils118 resulting in a vicious cycle. Thus, 
neutrophils play a role in the pathogenesis of preeclampsia by promoting placental 
hypoxia, systemic endothelial dysfunction and generation of local oxidative stress in the 
vasculature.  
 
C. Enhanced Vascular Reactivity to Ang II in Preeclampsia: 
Women with preeclampsia have hypertension by definition. Though normal 
human pregnancy is characterized by increased levels of circulating angiotensin II119, 
normal pregnant women are relatively resistant to the effects of infused angiotensin II 120. 
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In contrast, the vasculature of preeclamptic women is highly sensitive to the 
vasoconstrictive effect of angiotensin II and also other vasopressors46, 121, 122. In a 
prospective clinical study of primigravid women (women who are pregnant for the first 
time), Norman Gant and colleagues demonstrated enhanced vascular responsiveness to 
Angiotensin II (Ang II) in women who go on to develop preeclampsia123. Primigravid 
women who went on to develop pregnancy-induced hypertension required a lower dose 
of Ang II infusion in order to elicit a pressor response of > 20 mmHg diastolic pressure as 
compared to those who remained normotensive throughout pregnancy. Results of the 
study are depicted graphically in Figure 3. This classic paper established that increased 
sensitivity to Ang II induced pressor response preceded the development of 
preeclampsia123. Most studies following this work reported that neither renin, renin 
substrate nor Ang II were elevated in preeclamptic women48, 124 supporting a role of 
enhanced vascular reactivity to Ang II in preeclampsia. In this section I will briefly 
review the regulation and mechanism of action of Ang II and go on to explain how 
neutrophil release of ROS could enhance the vasoconstrictive action of Ang II via 
activation of the RhoA kinase pathway. 
 
i. Angiotensin II and VSMC Contraction: 
 
a. Angiotensin II (Ang II) Generation   
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i. ACE pathway: Renal renin catalyses the conversion of angiotensinogen to 
angiotensin I (Ang I). Angiotensin converting enzyme (ACE) within the lung 
vasculature catalyses the release of histidyl-leucine from the COOH-terminus of Ang 
I to yield the octapeptide vasopressor, Ang II125.  
ii. Another mechanism of Ang II generation resides within the heart and systemic 
vasculature, the chymase/non-ACE pathway: Chymase or chymotrypsin like serine 
protease (CLP) was first found in mast cells126. Subsequently, it was shown to be 
present within the heart 19and isolated human arteries127. Eighty percent of the Ang II 
in the human heart comes from chymase dependent conversion of Ang I to Ang II19.  
 
b. Mechanism of Action:  
The vascular effects of Ang II are predominantly mediated by the AT1 receptor 
(Fig.4). The downstream cell-signaling molecules involved are phospholipase C, rise in 
intracellular calcium levels, protein kinase C (PKC)128, tyrosine kinases129, mitogenesis 
associated protein kinase (MAPK) and the janus kinase (JAK) pathways. Tyrosine kinase 
and MAPK modulate contraction in smooth muscle through a variety of mechanisms129. 
 
i)    VSMC contraction: Myosin light chain kinase (MLCK) is a Ca-calmodulin 
dependent enzyme that phosphorylates the regulatory myosin light chain (MLC) 
permitting its activation by actin130. Cross-bridge cycling of phosphorylated MLC and 
actin results in VSMC contraction. Agonists like Ang II and ET-1 activate Ca++ influx 
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through ligand-gated and store operated Ca++ channels in VSMC131. However, the work 
of Fujihara suggests that agonist induced tonic contraction is largely a result of Ca++ 
sensitizing effect of activated RhoA/Rho kinase pathway132 with a possible small 
contribution of Ca++ influx that maintains [Ca++]i above basal levels. Ang II induced 
VSMC contraction and hypertrophy is mediated via AT1-R [G-Protein coupled receptor 
(GPCR)] activation of Rho/RhoA kinase and protein kinase C (PKC) pathway133.  
 
ii)    Calcium sensitization pathways: The RhoA/Rho kinase pathway is a major 
mechanism of Ca++ sensitization that acts by inhibition of smooth muscle myosin 
phosphatase (Fig 4)134. In VSMCs, several agonists including Ang II stimulate Rho 
kinase activity by increasing GTP-bound Rho A150. Rho activation also up-regulates 
AT1-R mRNA expression, thus enhancing Ang II effects via receptor up-regulation135. 
Activated RhoA kinase phosphorylates the regulatory subunit of MLC phosphatase, 
MYPT1. This inhibits MLC phosphatase and slows de-phosphorylation of MLC134, 136, 
137. Increased levels of pMLC lead to Ca++ sensitization. Ang II induced Rho/RhoA 
kinase activation requires a tyrosine kinase, PYK-2, and its upstream activator, PKC-δ. 
PYK-2 may signal to Rho via phosphorylation and activation of Rho GEF138. Y-27632, a 
selective RhoA kinase inhibitor139, can induce Ca++- desensitization by inhibiting Ang II 
induced MYPT1 phosphorylation at threonine 696133. 
Evidence for a role of PKC in Ca++ sensitization of the contractile apparatus of 
VSMC’s comes from sustained VSMC contraction by direct activation of PKC by 
phorbol esters without significant changes in [Ca++]i140, 141. PKC activation results in 
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activation of CPI-17, a phosphatase-1 inhibitor, which inhibits MLC phosphatase leading 
to Ca++ sensitization142, 143. ET-1 increases PKC activity in VSMC144and thereby 
increases vascular reactivity to Ang II. 
Calcium desensitization is mediated by NO and cyclic guanosine monophosphate 
(cGMP) 145, 146. cGMP mediated protein kinase (PKG) antagonizes RhoA/Rho kinase 
pathway by reversal of G-protein coupled inhibition of MLC phosphatase by PKG 
activation147, 148. Cyclic AMP and cGMP activate A-kinase & G-kinase149 respectively, 
which phosphorylate site A of MLCK, decreasing its affinity for Ca-calmodulin 10-
fold150. In this way NO and cGMP reduce MLCK activity leading to Ca++ desensitization. 
 
iii)    Sympathetic Nervous System: In vivo, vascular smooth muscle is under the 
influence of the sympathetic system. Ang II inhibits K+ currents in neurons leading to 
increased Ca++ current and increased neuronal firing leading to norepinephrine (NE) 
release and activation of the sympathetic system151. Although sympathetic activity is 
decreased during normal pregnancy it is reversibly increased in stress and in women with 
preeclampsia152. Stress related sympathetic stimulation and NE release might have a 
contributory role in the development of preeclampsia153-155. Treatment of cultured 
sympathetic cells with preeclamptic plasma results in significant increase in NE 
release156. NE is the most important neurotransmitter of the sympathetic system. In 
subcutaneous resistance arteries of preeclamptic women, NE induced Ca++ 
sensitization157, 158, which was previously shown to be associated with an increase in 
pMLC as a result of decreased MLC phosphatase activity mediated via PKC159. However, 
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as opposed to Ang II induced hypertension, NE induced hypertension did not increase 
superoxide production or oxidase expression160. 
 
ii. Sources of Ang II in Preeclampsia:  
During pregnancy, apart from the renal renin angiotensin aldosterone system 
(RAAS), there is also the placental RAAS 161. Placental hypoxia in preeclampsia can 
induce increased ACE mRNA expression and activity in the venous endothelial cells of 
the stem villous which is the main site of conversion of Ang I to Ang II in the placenta162. 
The levels of ACE and Ang II are increased in placental tissues and umbilical venous 
plasma of preeclamptic women163. Shah introduced the concept that due to reduced 
perfusion of the utero-placental unit in preeclampsia, the placenta behaves like the 
clipped kidney of the 2 kidney 1 clip Goldblatt model164. In concurrence with the 
implication of placental RAAS activation (akin to the clipped kidney) in preeclampsia, 
renin gene expression and Ang II levels were 3-fold higher in the decidua and chorionic 
villi of preeclamptic women165. Preeclampsia is characterized by up-regulation of AT1R 
in the decidua166, however, the aminopeptidase-A (AP-A) enzyme cleaves N-terminal 
aspartyl acid residue of Ang II to form its inactive metabolite Ang III167 so the enzyme 
acts as a feto-maternal barrier to transport of Ang II across the placenta168. AP- A is 
induced by Ang II via AT1 and AT-2 receptors. The AP-A system is ideally localized 
within the basal zone of the synctiotrophoblast to effectively remove Ang II from the 
fetal circulation (up to 90%)169.  
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Apart from placental Ang II, endothelial cells can be a source of local release of Ang II 
on VSMCs. Earlier studies have shown renin substrate, renin activity, Ang I and Ang II 
generation within endothelial cells170, 171. Increased CLP and chymase activity is seen in 
women with preeclampsia172, 173. Thus, CLP/chymase dependent generation of Ang II 
and/or ET-1 may regulate contractile function of the VSMC in preeclampsia. Also, 
increased basal release of angiotensin II and endothelial CLP/chymase activation was 
reported in response to stimulation by preeclampsia placental conditioned medium (PE-
CM)172. Basal release of Ang II increased in a concentration dependent manner with 
application of apical chymotrypsin was inhibited by chymotrypsin inhibitor and 
unaffected by ACE-I. This suggests additional angiotensin II generation by the 
endothelial cells via the chymase/non-ACE pathway right onto the vascular smooth 
muscle cells of the vessel walls in preeclamptic women. In preeclampsia high levels of 
Ang II locally can induce phosphodiesterase 1A1 (PDE1A1) which degrades cGMP to 
5’-GMP174. Inactivation of cGMP by AngII may also play a role in the development of 
Ca++- sensitization in VSMCs. PE-CM also induced translocation of the AT-1 receptor 
from the cytosol to the nuclei which suggests AT-1 receptor up-regulation by the PE-
CM172 potentially leading to increased sensitivity to Ang II. 
 
iii. Role of Angiotensin II in preeclampsia:  
Angiotensin II contributes to ROS production and inflammatory responses via 
activation of NADPH oxidase and NF-κB in trophoblasts and VSMCs175, 176. This effect 
is important physiologically as even a low dose of Ang II (10-10M) has been shown to 
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increase NADPH oxidase derived ROS in cultured VSMCs177, 178. Baseline ROS 
production by vascular NADPH oxidase is low. On stimulation, ROS production by 
vascular NADPH oxidase is only a third of what neutrophils produce, but it is sustained 
for a longer duration179. Long term (hours to days) ROS generation is mediated by 
p22phox gene up-regulation180 while short term ROS production probably involves 
assembly of component subunits into a functional oxidase and/or subunit biochemical 
modifications181. Increased amount of superoxide produced in VSMCs combines with 
NO to form ONOO-182. Peroxynitrite contributes to vasoconstriction and vascular 
injury183. Increase in NO degradation rather than reduced production impairs endothelium 
dependent vasodilation184. Angiotensin II stimulated ROS production within the VSMC 
induces degradation of I-κB leading to NF-κB activation185, 186. Ang II and AT1-AA also 
stimulate endothelial cell expression of tissue factor (TF)187. Enhanced TF activity in 
preeclampsia is associated with enhanced cell adhesion and migration of immune cells188 
promoting neutrophil adhesion, emigration and synthesis of TNF-α and IL-6189. 
Angiotensin II also promotes expression of soluble fms-like tyrosine kinase (sFlt-1) in 
decidual tissue, sFlt-1 is an antagonist of VEGF and placental growth factor190 believed 
to play a role in the pathogenesis of preeclampsia by interference with placentation and 
vascular remodeling.  
 
D. Role of neutrophils in enhanced vascular reactivity to Ang II in preeclampsia 
There are a number of ways neutrophils could cause vasoconstriction or enhance 
vascular reactivity to Ang II. Direct vasoconstrictive effects of thromboxane A2 released 
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by activated neutrophils infiltrating the systemic vasculature of preeclamptic women191 
could  contribute to hypertension in preeclampsia in addition to ROS generation by 
neutrophils which impairs stability of the endothelium derived vascular relaxing factor, 
NO192. Neutrophil production of hydroxyl radicals, superoxide anions and iron dependent 
reactive species can impair endothelium dependent relaxation193. High concentrations of 
ROS inhibit the PI3K/Akt pathway decreasing endothelial NO production and thus 
increasing vascular tone194, 195. ROS are known to activate the Rho kinase pathway in a 
rat model of Ang II induced hypertension196. Neutrophil release of ROS acting via the 
Rho kinase pathway could increase [Ca++]i sensitivity to Ang II. ROS can also stimulate 
release of ET-1197. ET-1 is a vasoconstrictor that also enhances [Ca++]i sensitivity in 
VSMC’s198. Relaxin is a hormone which when incubated with human neutrophils causes 
a reduction in CD11b expression, superoxide generation, [Ca++]i, release of granules and 
chemotactic migration199. Relaxin is a potent vasodilator and its levels decline with 
advancing gestation. In preeclampsia, low levels of relaxin are associated with 
vasoconstriction200 and possibly neutrophil activation secondary to loss of the regulatory 
control of relaxin. 
Neutrophil release of pro-inflammatory cytokines like IL-6 and TNF-α can 
activate the sympathetic nervous system201. Three-fold higher sympathetic nerve activity 
is seen in preeclamptic women as compared to normotensive pregnant women202. IL-6 
treated rats have higher plasma renin activity, enhanced vasoconstriction, decreased 
pressure natriuresis and they develop hypertension203. TNF-α infusion causes 
hypertension associated with transcriptional up-regulation of the ET-1 gene in the kidney, 
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placenta and vasculature204. TNF-α released by neutrophils can contribute to ROS 
production and oxidative stress generation by specifically stimulating superoxide 
production at the CoQ site of the electron transport chain in the mitochondria205. Small 
concentrations of TNF-α and IL-6 cause a reduction in acetylcholine induced vasodilation 
and increased production of endothelium derived contracting factors like ET-1206, 207. 
Also, estradiol, levels of which are high in pregnancy, enhances leukocyte binding to 
endothelial cells via an increase in TNF-α induced adhesion molecules promoting further 
neutrophil infiltration within the systemic vasculature of preeclamptic women. Neutrophil 
release of TNFα might increase basal vascular tone by decreasing NO production and by 
interfering with insulin-mediated vasodilatation in preeclampsia208.  
 
E. Role of Matrix Metalloproteinase-1 
Along with neutrophil infiltration and vascular inflammation, MMP-1 expression 
is significantly increased in the vasculature of preeclamptic women (Estrada-Gutierrez, 
Walsh, unpublished). Immunohistochemistry showed significantly greater staining for 
MMP-1 in the endothelium, vascular smooth muscle and infiltrating leucocytes. 
Consistent with a 7-fold increase in MMP-1 gene expression, pro-MMP-1 as well as 
activated MMP-1, were more abundant in omental vessels from preeclamptic women as 
compared to normal pregnant women. Moreover, plasma level of MMP-1 is also 
significantly higher in preeclamptic women. Thus we wanted to examine a role for MMP-
1 in preeclampsia.  
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MMP-1 is known for its collagenolytic properties and has been widely studied 
with respect to its role as a collagenase. However, in recent years MMP-1 has been 
shown to activate the protease activated receptor-1 (PAR-1)209, 210, also known as 
thrombin receptor. PAR-1 is a G-protein coupled receptor (GPCR) that is involved in a 
number of cellular regulatory and signaling pathways. MMP-1 cleaves the N-terminal 
end of PAR-1 two amino acids distal to the cleavage site of thrombin. This forms a new 
N-terminus that binds to the tethered ligand binding site leading to PAR-1 activation211-
213. MMP-1 induced N-terminal proteolytic cleavage resulting in irreversible PAR-1 
activation is unique to PARs. Therefore PAR signaling is tightly regulated by rapid 
desensitization at the plasma membrane by β-arrestins214, rapid phosphorylation and  
receptor trafficking215.  In endothelial cells PAR-1 undergoes rapid agonist-induced 
internalization, is delivered to lysosomes for degradation, and receptors from subcellular 
location are translocated to the surface upon PAR-1 agonist stimulation216. 
 
Our lab recently reported significantly increased PAR-1 expression in human 
omental vessels from preeclamptic women with little to no PAR-1 expression in normal 
pregnant women (Estrada-Gutierrez, Walsh, unpublished). Also endothelial cells express 
PAR-1 and MMP-1 can cause PAR-1 mediated endothelial activation217. Thus in normal 
pregnant women, MMP-1 can activate endothelial PAR-1 leading to endothelial cell 
activation and release of endothelial cell granules containing vWF, IL-8 and ET-118. 
Endothelin-1 is the only endothelin produced by endothelium and it acts on VSMC via 
the ETA receptor to cause vasoconstriction and smooth muscle proliferation. Endothelin-1 
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also contributes to increased vessel reactivity to vasoconstrictors like Ang II and NE. 
Thus, MMP-1 can contribute significantly to the pathogenesis of preeclampsia by PAR-1 
mediated endothelial activation and release of ET-1. 
In preeclampsia neutrophils could be a source of MMP-1218, as 
immunohistochemistry staining for MMP-1 and neutrophils co-localize. However, our 
lab has shown diffuse staining for MMP-1 within the vascular smooth muscle and that 
neutrophils and neutrophil products like ROS and TNF-α induce MMP-1 expression by 
VSMC in vitro (Estrada-Gutierrez, Walsh, unpublished). Vascular smooth muscle cells 
express PAR-1219. Protease activated receptor-1 has also been implicated in increased 
leucocyte endothelial adherance and rolling, migration of leukocytes from the vasculature 
into inflamed tissues220 and causing edema via a breach in endothelial integrity221. Via 
PAR-1 activation, our lab has shown that MMP-1 induces VSMC production of IL-8 and 
collagen fragments, which are chemotactic to neutrophils and promote neutrophil 
infiltration and vascular inflammation (Estrada-Gutierrez, Walsh, unpublished). Thus, 
neutrophils and MMP-1 may be co-conspirators in the pathogenesis of preeclampsia. 
 
F. Purpose of Investigation  
Women who develop preeclampsia have enhanced vascular reactivity to Ang II 
and decreased sensitivity to insulin. Neutrophil infiltration and vascular inflammation 
was recently described within the systemic vasculature of preeclamptic women. 
Neutrophils release toxic compounds like reactive oxygen species (ROS) and tumor 
necrosis factor-alpha (TNF-α) that could adversely affect the vasculature. 
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Neutrophil release of ROS might enhance vessel reactivity to Ang II. The primary 
mechanism to enhance vessel reactivity is the RhoA kinase (ROK) pathway. ROK 
phosphorylates MYPT1, the regulatory protein of MLC phosphatase. This inhibits MLC 
phosphatase and thus inhibits de-phosphorylation of myosin light chains (MLC). The 
resultant increase in phosphorylated MLC (pMLC) enhances vascular smooth muscle cell 
sensitivity to intracellular calcium. ROS activate ROK, so neutrophils could enhance 
vessel reactivity by release of ROS leading to activation of the ROK pathway.  
Neutrophil release of ROS and TNFα might also adversely affect vascular 
function by promoting insulin resistance as a result of down-regulating phosphatidyl 
inositol 3-kinase (PI3K) and thus inhibiting GLUT-4 receptor translocation in vascular 
smooth muscle cells. TNFα could down-regulate the activity and/or expression of PI3K 
because it is the direct downstream target of insulin receptor substrate-1 and it is also 
upstream of phosphorylated Akt, both of which are inhibited by TNFα. ROS might 
down-regulate PI3K by activating RhoA, which inhibits PI3K/Akt signaling in 
endothelial and vascular smooth muscle cells. 
The following are the specific aims and hypotheses for my thesis dissertation, 
which are designed to elucidate the role of neutrophils and neutrophil products in the 
development of enhanced vessel reactivity to Ang II, vasoconstriction and insulin 
resistance in preeclampsia. 
 
G. Overall Hypothesis  
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Specific Aim 1: To determine if neutrophils or neutrophil products, ROS and 
TNFα , enhance vessel reactivity to vasoconstrictors like Ang II and NE. 
 
Hypothesis 1: Activated neutrophils enhance vessel reactivity to Ang II. 
Neutrophils isolated from healthy non-pregnant women will be activated with IL-
8 and perfused at physiologic concentration through the lumen of human omental 
resistance arteries mounted on a myograph system. The vasoconstrictive response to Ang 
II will be compared to the response in the absence of neutrophils. To determine the 
mechanisms underlying enhanced vessel reactivity superoxide dismutase/catalase will be 
used to quench ROS and Y-27632 to inhibit ROK. 
 
Hypothesis 2: Neutrophil products, ROS and TNFα, will enhance vessel reactivity to 
Ang II. 
To test this hypothesis, human resistance arteries will be dissected from omental 
fat obtained from normal pregnant women and mounted on a myograph system to assess 
vasoconstrictive response to Ang II in the presence and absence of neutrophil products, 
ROS and TNFα. Pharmacologic inhibitors, superoxide dismutase/catalase and Y-27632 
will be used to determine the mechanism underlying neutrophil mediated enhanced vessel 
reactivity to Ang II. 
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Hypothesis 3: Neutrophils or neutrophil products will activate RhoA kinase in human 
vascular smooth muscle cells as evidenced by increased phosphorylation of MYPT1 and 
MLC. 
To test this hypothesis, primary cultures of human vascular smooth muscle cells 
will be co-cultured with neutrophils (activated using arachidonic acid) or treated with 
neutrophil products, ROS and TNFα, for 24 hrs, after which cells will be harvested. The 
cell lysates will be analysed using Western blotting to quantify the relative amounts of 
phosphorylated and non-phosphorylated MLCs. Western Blotting using a specific 
antibody to pMYPT1-Thr696 will be done for quantification of MYPT1 phosphorylation. 
To test this hypothesis ex-vivo, human omental vessels will be dissected and treated with 
ROS or Dulbecco’s phosphate buffered saline (D-PBS) alone. Within 5 minutes, the 
vessels will be flash frozen in liquid nitrogen and processed for determination of RhoA 
kinase activity using radioisotope labeled adenosine tri-phosphate (ATP) assay. 
 
Hypothesis 4:  ROS will enhance vessel reactivity to NE. 
To test this hypothesis, human resistance arteries will be dissected from omental 
fat obtained from normal pregnant women and mounted on a myograph system to assess 
vasoconstrictive response to NE in the presence and absence of ROS. Pharmacologic 
inhibition of RhoA kinase with Y-27632 will be used to determine if activation of RhoA 
kinase underlies ROS mediated enhanced vessel reactivity to NE. 
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Specific Aim 2: To determine if MMP-1 causes vasoconstriction or enhances vessel 
reactivity to Ang II via activation of PAR-1 and ET-1 release from endothelium. 
 
Hypothesis 1: MMP-1 causes dose-dependent vasoconstriction in human omental vessels.  
To test this hypothesis, human resistance arteries will be dissected from omental 
fat obtained from normal pregnant women and mounted on a myograph system to assess 
vasoconstrictive response to varying doses of MMP-1. To determine the mechanisms 
underlying MMP-1 induced vasoconstriction, SCH-79797, a PAR-1 inhibitor, and BQ-
123, an ETA receptor blocker, will be used. 
 
Hypothesis 2:  MMP-1 enhances vessel reactivity to Ang II.   
To test this hypothesis, human omental fat arteries from normal pregnant women 
will be used to assess vasoconstrictive response to varying doses of Ang II in the 
presence and absence of a low dose of MMP-1. To determine the mechanism underlying 
enhanced vessel reactivity, SCH-79797 and BQ-123 will be used. 
 
Specific Aim 3: To determine if neutrophils or neutrophil products could cause 
insulin resistance by affecting PI3K. 
Hypothesis 1: Neutrophils and/or neutrophil products will decrease protein expression of 
the regulatory (p85α) and catalytic (p110α) subunits of PI3K. 
To test this hypothesis, human vascular smooth muscle cells will be co-cultured 
with neutrophils (activated using arachidonic acid) or treated with neutrophil products, 
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ROS and TNFα, for 48 hours, after which cells will be harvested and frozen at -80˚C 
until analysis. The protein cell lysate will be analyzed by Western Blotting using specific 
antibodies for the regulatory (p85α) and catalytic (p110α) subunits of PI3K. All 
comparisons will be made to the control with culture medium alone. 
 
In summary, my dissertation will examine if infiltration of neutrophils into the 
systemic vasculature of preeclamptic women can explain the enhanced reactivity to Ang 
II and insulin resistance characteristic of preeclampsia. It will also explore the 
mechanisms by which neutrophils and neutrophil products enhance reactivity to Ang II 
and determine if these phenomena are generalized or specific to Ang II. It will also 
explore the role of MMP-1 in vasoconstriction and enhancement of vessel reactivity to 
Ang II. 
 
H. Significance of this research 
 
If neutrophils or neutrophil products, ROS or TNF-α, are found to enhance vessel 
reactivity to Ang II, then neutrophil infiltration and inflammation can explain the 
increased vascular reactivity to Ang II in preeclampsia and provide the first explanation 
for development of hypertension in preeclampsia. Moreover, if MMP-1 causes dose 
dependent vasoconstriction or enhances vascular reactivity to Ang II, it may provide 
alternate or additional evidence for explaining development of hypertension in 
preeclampsia. If increased vessel reactivity to Ang II by neutrophils and ROS is mediated 
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via the RhoA kinase pathway, the role of RhoA kinase inhibitors could be explored as 
treatment options for preeclampsia. If MMP-1 causes vasoconstriction and enhances 
vessel reactivity to Ang II via PAR-1 and ET-1, then PAR-1 inhibitors and ETA receptor 
blockers could be studied for treatment of preeclampsia. If neutrophils are implicated in 
the pathogenesis of preeclampsia, neutrophil-neutralizing antibodies are another 
possibility that may be useful in preventing development or arresting progression of 
preeclampsia by prevention of neutrophil adhesion and infiltration within the maternal 
systemic vasculature. 
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Figure 1. Theory of neutrophil activation in the intervillous space in placenta.  
Neutrophils are activated as they circulate through the inter-villous space by lipid 
peroxides secreted by the placental trophoblast cells. Neutrophils return to the maternal 
compartment to cause vascular damage by generation of reactive oxygen species and 
oxidative  stress. (Used with permission of artist. From Walsh, S. W. The role of 
oxidative stress and anti-oxidants in preeclampsia. Contemporary OB/GYN, 1997; 42: 
113-124)
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Figure 2. Pathways of neutrophil induced oxidative stress production. Interactions 
between reactive oxygen intermediates and reactive nitrogen intermediates resulting in 
nitric oxide (NO) scavenging by superoxide (O2.) production leading to formation of 
peroxynitrite (ONOO-). 
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Figure 3. Data redrawn from Gant et al (The Journal of Clinical Investigation, Nov 
1973,Vol52, pg 2682-2689). This study clearly established development of sensitivity to 
the pressor response of Angiotensin II during pregnancy as a predecessor to the 
development of preeclampsia.  
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Figure 4. RhoA kinase pathway.  Release of reactive oxygen species (ROS) by activated 
neutrophils may activate RhoA kinase (ROK) to result in phosphorylation (p) of the 
regulatory myosin light chain (MLC) phosphatase target subunit 1 (MYPT1), which 
inhibits the MLC phosphatase enzyme (MLCP). Inhibition of MLCP leads to decreased 
MLC dephosphorylation, an accumulation of phosphorylated myosin light chains and 
thus enhanced contraction for a given change in intracellular calcium level by the same 
agonist concentration. (CaM-calcium calmodulin complex, MLCK- myosin light chain 
kinase). 
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Figure 5. Matrix metalloproteinase-1 (MMP-1) activation of PAR-1. MMP-1 induced 
cleavage of the N-terminal end of the PAR-1 receptor generates a new N-terminal end 
that allows inter-molecular interaction of the tethered ligand to the tethered ligand 
binding site on the exo-domain of PAR-1, which results in activation of PAR-1. 
Activation of endothelial PAR-1 can lead to endothelial activation with release of 
endothelial cell granule contents like von Willebrand’s factor (vWF) and endothelin-1 
(ET-1). 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
A. Myograph System: 
 
i. Collection of Fat 
 
Omental fat biopsies (approximately 3 cm x 2 cm x 0.5 cm) were collected from 
normal pregnant women and women with preeclampsia undergoing cesarean section at 
Medical College of Virginia (MCV) Hospitals, Virginia Commonwealth University 
(VCU) Medical Center. The fat was placed in a labeled bottle with isotonic normal saline. 
The bottle was kept in a refrigerator and transferred to the laboratory on ice as soon as 
possible. After the vessel arrived, it was immersed in cold (0-4˚C) Dulbecco’s Phosphate 
Buffered Saline (D-PBS) containing glucose, sodium pyruvate, calcium chloride and 
magnesium chloride (Gibco, Invitrogen) on a silicone dissection dish pre-cooled to 4˚C. 
 
ii. Vessel Dissection 
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The fat biopsy was pinned down on the silicone dissection dish in cold (0-4˚C) D-
PBS to visualize the vasculature under a dissection microscope (Olympus, B061, zoom 
1:7.5). A vessel of approximately 200-500 µ diameter was selected for dissection. The fat 
around the vessel up to a length of 2 cm was dissected and discarded, while being careful 
to leave about 1 mm of fat around the vessel to avoid damaging the vessel. Then, the 
vessel was fixed on the dissection dish using two pins at either end. The artery was 
identified from the vein (often the artery and vein ran together) (Fig.6). Fine dissection 
was done using a 0.075 mm tip scissors (Fine Science Tools (FST) No.15001-08). Tissue 
was held with Dumont #55 forceps (FST no.11255-20) and gently pulled away from the 
artery. The scissors were used to cut the fat as close to the artery as possible, keeping the 
cutting edge of the scissors parallel to the length of the artery and the curved tip of the 
scissors pointing away from the artery. The artery was cleaned of adherent fat on all sides 
making note of branch points and being careful not to puncture the vessel at any point 
during dissection. A 1 cm length of vessel, free of branch points or potential punctures 
was selected for mounting. 
 
iii. Mounting of the vessel 
 
To mount the vessel on the myograph chamber (Fig.7) of the pressure myograph 
(Danish Myo Technologies (DMT), Denmark, Netherlands, Fig.8), four double looped 
ties were prepared using the suture tying forceps (FST 18025-10). Individual fibers 
isolated from embroidery thread (Walmart Superstores) were used to prepare the ties. Ten 
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ml D-PBS was added to the myograph chamber. The glass cannulae at both ends were 
tested for patency before mounting the vessel. The high vacuum grease which seals the 
transducer pin hole was inspected before beginning the experiment and replaced every 2 
weeks as per DMT recommendations. The myograph chamber was placed under the 
dissecting microscope and two ties were looped over the P2 side glass cannula. Once the 
selected vessel was mounted onto the tip of the P2 cannula, the ties were pulled over the 
vessel and tightened by gentle pulling as excessive force can break the tip of the glass 
cannula. Then, D-PBS was perfused through the vessel to gently flush out blood from the 
vessel lumen. The process was repeated to secure the other end of the vessel on the P1 
glass cannula (Fig.9). The myograph chamber was then placed on the stage of an inverted 
microscope (Nikon Eclipse, TS100). Pressure and flow were applied using either the 
DMT flow regulator or 10 ml syringes mounted at heights above the level of the vessel so 
as to generate 45 and 42 mmHg pressures at the inlet and outlet, respectively. Syringes 
reduced the amount of perfusate required to perfuse the vessel lumen to 10-15 ml as 
compared to 250 ml required for the Schott bottle of the DMT flow regulator system. 
When syringes were used flow was initiated from the P1 end with an inlet pressure of 45 
mmHg with the syringe placed at a height of 61.2 cm above the vessel (13.6 mm H2O = 1 
mmHg pressure) till D-PBS was seen to drip from the P2 end. Then, an outlet pressure of 
42 mmHg with the syringe placed at a height of 57.12 cm above the vessel level was 
applied at the P2 end. 
 
iv. Endothelium denudation 
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For endothelium denudation, one end of the vessel was mounted onto the P1 side of a 
glass cannula. The vessel was then gently pulled over the tip of the glass cannula over its 
entire length and rolled gently. It was pulled back off the glass cannula leaving about 2 
mm vessel length mounted onto the tip of the glass cannula. Then the two ties were 
pulled over the vessel to secure the vessel onto the glass cannula, after which the vessel 
lumen was gently flushed using D-PBS in a 1 ml syringe from the P1 end to flush out the 
endothelial cells. The other end of the vessel was then mounted and secured onto the P2 
side glass cannula. 
 
v. Data Recording  
 
The microscope focus was adjusted to obtain a clear view of the vessel. After 
connecting the Myo-Interface to the myograph chamber, the Myoview program on the 
computer was started. The microscope focus was adjusted to obtain a clear view of the 
vessel edges and lumen on the computer screen. Target inlet and outlet pressures were set 
to 45 and 42 mmHg, respectively, on the computer screen. A box was drawn around the 
vessel by clicking and dragging using the mouse for calibration by loading the 4X file (i.e 
objective lens magnification used). A new box was drawn around the clean edges of the 
vessel for analysis by the software. The graph configuration was set to a time range of 
3600 seconds, data rate at 10 seconds, inflow pressure 0-60 mmHg, outflow pressure 0-
60 mmHg, vessel diameter 200-600 µ, lumen diameter 50-500 µ, cross-sectional area 0-
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25000, and temperature to 0-40˚C. After graph configuration, history was reset and data 
logging was started. 
 
 
vi. Pressure and Force calibration 
 
Pressure and force calibration was performed periodically using a Big Ben 
manometer and the weights as described in the DMT Manual (Model 110P & 111P, 
version 3.2, pg 63-69). 
 
B. PASM isolation and cell culture 
 
Placental arterial smooth muscle (PASM) cells were isolated as described by Leik et 
al222. Briefly, placentas were obtained from normal pregnant women after informed 
consent (IRB# HM12361). The chorionic plate arteries were identified and dissected 
away from the placental tissue. The vessel was cut longitudinally to open the arterial 
lumen. The arterial sheet was cut into small pieces 3-5 mm, which were placed 
endothelial surface down onto 10 cm culture plates. Five ml of Medium-199 (M-199, 
Gibco, Invitrogen)) with 10% fetal bovine serum (FBS), 1% antibiotics and antimycotics 
(100X Anti-Anti, Gibco Cat#15240-062, penicillin 100 U/ml, streptomycin 100 µg/ml, 
amphotericin B 25 µg/ml) was added to the culture plates taking care not to disturb the 
adherent explants. Cells started to grow from the explants at the end of 1 week and were 
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confluent by about 4 weeks. At this point, they were exposed to M-199 without FBS for 
24 hours to eliminate contaminating endothelial cells and fibroblasts, which do not 
survive without serum. After 24 hours, PASM cells were replated with M-199 with 10% 
FBS and then passaged or frozen. Cells were used between passage 2 and 6 (Fig.10). 
 
C. Neutrophils, oxidative stress and TNF-α treatments: 
 
Control: Control treatments were fresh M-199 medium with 10% FBS and 1% 
antibiotics/antimycotics. 
Neutrophils: Neutrophils were isolated from whole blood obtained from normal non-
pregnant or normal pregnant women using Histopaque density gradient. For neutrophil 
isolation, 3 ml of Histopaque 1119 (Sigma, Cat#11191) was added to 15 ml conical tube. 
It was carefully layered with 3 ml of Histopaque 1077 (Sigma, Cat#10771) and then 6 ml 
of whole blood. This was centrifuged at 700 x g for 30 minutes at room temperature (18-
26˚C) to form 5 distinct layers comprised of plasma, mononuclear cells with platelets, 
histopaque 1077, granulocytes, histopaque 1119, and red blood cells (RBC) from top to 
bottom [Fig.11]. Fluid to within 0.5 cm of the granulocyte layer was aspirated and 
discarded. Cells from the granulocyte layer were aspirated and transferred to a new tube 
labeled granulocytes. Ten ml phosphate buffered saline (PBS) was added and the cells 
were centrifuged for 10 minutes at 200 x g at 4˚C. The PBS was removed with gentle 
aspiration and the cell pellet re-suspended in 10 ml of PBS and centrifuged for 10 
minutes at 200 x g at 4˚C. If the cell pellet had RBC’s, 3 ml of ice-cold ddH2O was added 
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to the cell pellet followed by vortexing for 30 seconds to lyse the RBC’s. After 30 
seconds, 1 ml of 0.6 M potassium chloride (KCl) was added to restore tonicity followed 
by centrifugation at 200 x g at 4˚C for 4 minutes. The supernatant was discarded and the 
cell pellet re-suspended in 1 ml of medium. 
To count the neutrophils, 10 µl of cell suspension was added to 90 µl of trypan blue 
dye and pipetted several times to mix well (dilution factor of 10). Ten µl of this 100 µl 
cell suspension with dye was loaded onto a hemocytometer for counting. Neutrophils in 
all four quadrants of the hemocytometer were counted and added together [4X= 
X1+X2+X3+X4] (Fig.12). This number [4X] was divided by four to get the average 
number of cells per square [X= X1+X2+X3+X4/4]. The concentration of neutrophils was 
calculated as average number of cells per square x dilution factor x 104 neutrophils/ml. 
Neutrophil activation was done using either 10-8 M IL-8 or 100 µM arachidonic acid. For 
activation using IL-8, 10 µg of recombinant human IL-8 from R&D Systems (Cat# 208-
IL) is reconstituted in 1 ml of sterile phosphate buffered saline containing 1% bovine 
serum albumin and aliquoted into aliquots containing 1 µg/100 µl. For a final 
concentration of 10-8M IL-8, 80 µl of 1 µg/100µl aliquot is used per 10 ml of D-PBS 
containing neutrophils. For activation using arachidonic acid, 10 µl of a 50 mg in 100 µl 
ethanol solution was added to 1.08 ml of PBS to form Solution A. Then, 16.6 µl of 
solution A was added to the 1 ml cell suspension and incubated in a rotator for 30 
minutes at 37˚C. 
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ROS: A reactive oxygen species (ROS) generating solution was made using 0.05 mM 
hypoxanthine (Hyp, Sigma, H-9377) and 0.003 U/ml xanthine oxidase (XO, Calbiochem, 
Cat#682151) in M-199 with 10% FBS. A 1 mM hypoxanthine stock solution was 
prepared by dissolving 0.0027 gm of Hyp (MW 136.1) in 20 ml of M-199 with 1% 
antibiotics-antimycotics and 10% FBS. Sonication for 30 minutes in a water bath was 
used for dissolving the Hyp. For a final concentration of 0.05 mM, 250 µl of 1mM Hyp 
solution was added to 4.75 ml of M-199 with 1% antibiotics/anti-mycotics and 10% FBS. 
XO (Calbiochem) was purchased as a 20 U/ml stock solution made from buttermilk. For 
culture, 0.75 µl of 20 U/ml XO was added to a T-25 flask containing 5 ml of M-199 with 
1% antibiotics/anti-mycotics and 10% FBS for a final concentration of 0.003 U/ml. 
 
TNF-α: To make a 1 ng/ml solution of TNF-α, 0.5 µl of 10 µg/ml recombinant human 
TNF-α (R&D Systems, Cat#210-TA) was added to a T-25 flask containing 5 ml of media 
[M-199 with 1% antibiotics/anti-mycotics and 10% FBS]. 
 
D. Protein extraction and quantification for Western blot 
 
To detect phosphorylated proteins phospho-MYPT1 and phospho-MLC along 
with total MYPT1 and MLC by Western blot, culture medium was carefully removed 
from adherent PASM cells in T-25 flasks. One ml of ice cold PBS was added to each T-
25 flask and aspirated to remove FBS. M-PER (237 µl, Pierce 78501) with 3 µl of Halt 
protease inhibitor cocktail (Pierce 78415) and 60 µl of phosphatase inhibitor cocktail set 
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III (Calbiochem) was added to each T-25 flask. The flasks were placed on a shaker for 5 
minutes. Cells were then scraped and the lysate transferred to a microcentrifuge tube to 
be centrifuged at 14000 x g for 10 minutes at 4˚C. The supernatant was collected and 
frozen at -80˚C. Protein concentration in the collected supernatant was quantified using 
the Pierce BCA Protein Assay Kit. 
 
E. Western blot methodology: 
 
For all Western blots, the Invitrogen Xcell Surelock system was used for 
electrophoresis and the Odyssey (Licor) system was used for scanning fluorescence 
tagged secondary antibodies. 
i. Sample Preparation: For MYPT1 and MLC, equal concentrations of protein for every 
sample were calculated and volumized to 45 µl. Three µl of 20X reducing agent and 12 µl 
of 5X Laemli’s were added. Samples were placed in boiling water at 100˚C for 15 
minutes followed by cooling on ice and centrifugation at 4˚C for 1 minute. The samples 
were then applied to the wells of the gel using gel loading pipette tips. Biorad All Blue 
protein standards were run in the first lane of every Western blot. 
 
ii. Antibodies, electrophoresis and transfer for phospho-MYPT1 & total MYPT1: 
 
a) Primary antibodies: 
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i) Rabbit polyclonal phospho-MYPT1 antibody (Cell signaling technologies, Cat#4563) 
in a 1:300 dilution. 
ii) Rabbit polyclonal MYPT1 antibody (Cell signaling technologies, Cat#2634) in a 
1:1000 dilution. 
iii) Mouse monoclonal anti-β actin Ig (Sigma, A2228) in a 1:10,000 dilution. 
 
b) Secondary antibodies: 
i) IRDye 800 anti-mouse antibody (Licor) in a 1:30,000 dilution 
ii) AlexaFluor 680 goat anti-rabbit antibody (Invitrogen) in a 1:2500 dilution 
 
Tris-Glycine SDS gels (6%) were cast using the Biorad casting system and 1.5 mm 
combs. For a 15 ml gel, 7.9 ml ddH2O, 3.0 ml 30% acrylamide mix, 3.8 ml 1.5 M Tris at 
pH 8.8, 0.15 ml of 10% SDS, 0.15 ml of 10% ammonium persulfate (Fischer, BP179-25) 
and 12 µl of TEMED (N, N, N’, N’- Teramethylethylenediamine from Sigma, T9281). 
With sample loading of at least 50 µg protein/well, electrophoresis was run at 125V for 1 
hour 50 minutes. After electrophoresis, the gel was washed with ddH2O followed by 
equilibration in methanol free transfer buffer for 15-20 minutes. PVDF membrane (0.45µ 
pore size, Millipore) was wetted in 100% methanol for 30 seconds followed by rinsing in 
ddH2O and equilibration in methanol free transfer buffer for 15 minutes. Ice cold 
methanol free transfer buffer was used to soak the blotting pads taking care to remove all 
air bubbles. The sandwich of blotting pads, gel and PVDF membrane was assembled and 
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transfer was run for 2.5 hours at 70V. Coomasie blue staining of the gel was used to 
confirm optimal transfer of protein. 
 
 
iii. Antibodies, electrophoresis and transfer for phospho-MLC and total MLC: 
 
a) Primary antibodies: 
i) Rabbit polyclonal phospho myosin light chain 2 (Ser19) antibody (Cell signaling 
technologies, Cat#3671) in a 1:3000 dilution. 
ii) Rabbit polyclonal myosin light chain 2 antibody (Cell signaling technologies, 
Cat#3672) in a 1:1000 dilution. 
iii) Mouse monoclonal anti-β actin Ig (Sigma, A2228) in a 1:10,000 dilution. 
b) Secondary antibodies: 
i) IRDye 800 anti-mouse antibody (Licor) in a 1:30,000 dilution. 
ii) AlexaFluor 680 goat anti-rabbit antibody (Invitrogen) in a 1:10,000 dilution. 
Tris-Glycine SDS gels (12%) were cast using the Biorad casting system and 1.5 mm 
combs. For a 15 ml gel, 4.9 ml ddH2O, 6.0 ml 30% acrylamide mix, 3.8 ml 1.5 M Tris at 
pH 8.8, 0.15 ml of 10% SDS, 0.15 ml of 10% ammonium persulfate (Fischer, BP179-25) 
and 6 µl of TEMED (Sigma, T9281). With sample loading of at least 50 µg protein/well, 
electrophoresis was run at 125V for 1 hour 50 minutes. After electrophoresis, the gel was 
washed with ddH2O followed by equilibration in methanol free transfer buffer for 15-20 
minutes. PVDF membrane (0.2µ pore size, Millipore) was wetted in 100% methanol till 
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the opaque membrane turned a translucent gray color, followed by rinsing in ddH2O and 
equilibration in 40% methanol transfer buffer for 15 minutes. Ice cold 40% methanol 
transfer buffer was used to soak the blotting pads taking care to remove all air bubbles. 
The sandwich for transfer was assembled and transfer run for 1.5 hours at 25V. 
Coomassie blue staining of the gel was used to confirm optimal transfer of protein. The 
membrane was immersed in 0.25% glutaraldehyde at room temperature for 45 minutes to 
fix the myosin light chains and washed with PBS before proceeding with blocking. 
 
 
iv. Primary and secondary antibody incubation 
 
For all Western blots, the membrane was marked with pencil, cut or fold to identify 
the face of the membrane in approximation with the gel. The membrane was washed in 
ddH2O for 5 minutes and blocked in 1:1 diluted Odyssey Blocking buffer (Licor) and 
PBS for 1 hour at room temperature. The membrane was then washed once with PBS for 
5 minutes. After that, the membrane was incubated overnight at 4˚C in the primary 
antibody solution comprised of 1:1 PBS and Odyssey Blocking Buffer with 0.1% Tween-
20. The next day the membrane was washed 4 times for 5min each in PBS with 0.1% 
Tween-20. Henceforth, foil wrap was used to protect the membrane from light. The 
membrane was incubated for 1 hr at room temperature with secondary antibody solution 
in 1:1 PBS and Odyssey blocking buffer with 0.1% Tween-20 and 0.01% w/v of SDS. 
The membrane was washed 4 times for 5 minutes each in PBS with 0.1% Tween-20. 
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Then the membrane was washed 4 times for 5 minutes each in PBS alone and twice for 5 
minutes each in ddH2O. The membrane was scanned using the Odyssey system. The 
glass and silicon mat were cleaned before placing the membrane on the Odyssey scanner. 
 
v. Membrane stripping using low pH: 
 
A stripping buffer of 25 mM glycine-HCl at pH 2.0 with 1% SDS was prepared by 
addition of 1.88 gm glycine and 10 gm SDS to 600 ml ddH2O and titrated to a pH of 2.0 
using 1 N HCl. It was then volumized to 1 L with ddH2O. For membrane stripping, the 
membrane was placed in the stripping buffer for 30 minutes with agitation and then 
washed in PBS for 10 minutes twice. After stripping, blocking of the membrane for the 
next antigen detection step was performed. 
 
vi. Densitometric analysis 
 
Quantification of bands obtained on Western blots was done by densitometric 
analysis of the bands in the ‘Details View’ of the Odyssey software using the median 
method for calculation of background. The average intensity obtained for each band was 
normalized to that of β-actin for the same lane. The band intensity of each treatment was 
then calculated as a percent value of the normalized value of the control lane for that 
experiment. The percent value of the control was used for statistical analysis. 
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Figure 6. Identification of the artery. The artery can be identified from the vein by 
looking for branch points. Branches off the artery are sharp and shaped like a V while 
those from veins are U-shaped. The vein is collapsible on pressure and shows slow or no 
return of blood flow when pressed against. Pressing the artery against the silicone dish to 
judge thickness of the vessel wall and return of blood flow damages the vessel, so a 
length of vessel distal or proximal but not including the area pressed should be used for 
the experiment. The artery is usually the narrower of the two vessels.  
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U -shaped 
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Vein 
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Figure 7. Myograph Chamber. Pressure myograph system with in-built pressure and 
force transducers and a perfusion system with inlet (P1) and outlet (P2) (From DMT 
manual, model 110P & 111P, version 3.2). 
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Figure 8. DMT Pressure Myograph. The equipment comprised of the myograph 
chamber placed on the stage of the inverted microscope and connected with the 
Myointerface and the flow and pressure regulator placed on top of the Myointerface 
with Schott bottles for perfusion of the vessel. The Myointerface connects the 
myograph chamber to the computer enabling data recording and control of the 
myograph chamber through the computer program settings.  
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Figure 9. Myoview image of the mounted vessel, showing the tip of the glass cannula 
within the vessel lumen. 
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Table 1. Configuration settings of the software used for myograph experiments 
 
Time range (s) 3600                Data Rate(s) 10 
Inflow pressure (mmHg) 0 60 
Outflow Pressure (mmHg) 0 60 
Vessel diameter (microns) 250 500 
Lumen diameter (microns) 50 500 
Cross-sectional Area 0 25000 
Temperature (C) 0 35 
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Figure 10. Placental arterial smooth muscle (PASM) cell culture. PASM cells growing 
from chorionic plate arterial explants at A) 1 week, B) 2 weeks, C) 3 weeks and D) 4 
weeks. 
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D 
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Figure 11. Neutrophil Isolation by Histopaque Gradient Separation. The top layers up to 
0.5 cm above the granulocyte (neutrophil) layer were aspirated and discarded. The 
neutrophil layer was then aspirated and transferred to a new tube to be washed with PBS.
Monocytes/lymphocytes 
Whole Blood 
Erythrocytes Histopaque 1119 
Histopaque 1077 Histopaque 1119 
Histopaque 1077 
Granulocyte /neutrophils 
Centrifuge 
700g 30min 
Plasma 
 57
 
 
Figure 12. Cell counting grid of hemocytometer: Count all neutrophils within the red 
boxes and add them together (4X). Divide this number by 4 to get X. The volume of 
each square with the coverslip in place is 0.1 mm3. Therefore, cells per ml = average 
count per square x dilution factor x 104. 
X1 
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Chapter 3 
 
NEUTROPHILS ENHANCE VASCULAR REACTIVITY TO ANGIOTENSIN II 
VIA REACTIVE OXYGEN SPECIES ACTIVATION OF THE RHOA KINASE 
PATHWAY 
 
A. Introduction  
 
Preeclampsia is a hypertensive disorder of pregnancy that complicates 5-7% of all 
pregnancies resulting in significant maternal and fetal mortality and morbidity5.  
Recently, we showed significant infiltration of neutrophils into systemic vasculature of 
women with preeclampsia, which was associated with marked vascular inflammation95, 
96. We also found a similar vascular infiltration of neutrophils in obese women97 which 
may be of interest because obesity is a risk factor for preeclampsia, as well as chronic 
hypertension223. 
 
In 1973, Gant et al described enhanced vascular reactivity to angiotensin II (Ang 
II) in women predestined to develop preeclampsia123. However, mechanisms underlying 
this increased vascular reactivity remained elusive. The major mechanism of increased 
vascular reactivity is the RhoA kinase (ROK) pathway and reactive oxygen species 
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(ROS) activate this pathway134. When ROK is activated, it phosphorylates MYPT1 which 
inhibits myosin light chain phosphatase so myosin light chains (MLC) remain 
phosphorylated which enhances vascular reactivity.134 Therefore, for a given 
concentration of Ang II, vessel responsiveness would be enhanced. Neutrophils release 
inflammatory compounds that could cause vasoconstriction or enhance vessel reactivity 
to vasoconstrictors. For example, neutrophil release of ROS may enhance vessel 
reactivity by RhoA kinase pathway activation.  
 
In this study we used human omental vessels and cultured human vascular smooth 
muscle cells to test the hypothesis that neutrophils or neutrophil products (ROS, TNF-α) 
cause vasoconstriction by enhancing vessel reactivity to Ang II via the RhoA kinase 
pathway. 
 
B. Materials and Methods 
 
Study Subjects 
Omental fat biopsies (approximately 2 cm x 4 cm x 2 cm) were collected from 
normal pregnant women undergoing term C-section at MCV Hospitals, Virginia 
Commonwealth University Medical Center. Omental fat is vascularized tissue 
representative of the systemic vasculature. Neutrophils were isolated from whole blood of 
pregnant or non-pregnant female subjects using dual Histopaque (Sigma, St. Louis, MO) 
density gradient centrifugation as previously described191. Demographic data on the 
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subjects were (Mean±SD): age (27.5±6 years), systolic blood pressure (127±16 mmHg), 
diastolic blood pressure (74±11 mmHg), gestational age (39±1 weeks), birth weight 
(3387±506 grams). Twenty-one subjects were primiparous and 19 were multiparous. 
Mean lumen diameter of omental vessels studied was 287 ± 99 µ. The Office of Research 
Subjects Protection of Virginia Commonwealth University approved this study and all 
subjects gave informed consent. IRB No. HM12361 
 
Myograph Experiments 
The omental fat biopsy was placed in Dulbecco’s phosphate buffered saline (D-
PBS, Gibco Invitrogen, Carlsbad, CA) on a silicone dissection dish pre-cooled to 4˚C. A 
2 cm length of a vessel 200-500 µ diameter was dissected and mounted on glass micro-
cannulae of a myograph system (Model 110P, Danish Myo Technologies (DMT), 
Denmark, Netherlands). Endothelium was denuded by passing a fine metal wire through 
the vessel lumen. The vessel was immersed in 10 ml of D-PBS in the myograph chamber 
and secured at both ends using two 11-O silk suture ties at each end. The myograph 
chamber temperature was maintained at 37˚C and the vessel pressures maintained at 
constant inlet (45 mmHg) and outlet (42 mmHg) pressures to achieve flow through the 
vessel. Ang II dose response was run in 10-fold increments in concentrations 0.001-10 
µM. The vessel was challenged to 60µM KCl at beginning, end and in between 
treatments to ascertain vessel viability and to recharge intracellular calcium stores.  
Isolated neutrophils were re-suspended in 1 ml of D-PBS and counted using a 
hemocytometer. Neutrophils were activated using human recombinant interleukin-8 (IL-
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8, 10-8 M final concentration, R&D Systems, Minneapolis, MN). Neutrophils were 
perfused through the vessel in a physiologic concentration of ~2000/mm3 and after noting 
response to neutrophils alone the Ang II dose response was repeated.  The experiment 
was repeated in the presence of either superoxide dismutase (SOD, 5000 IU/ml, Sigma, 
St. Louis, MO) and catalase (150 U/ml, Sigma, St. Louis, MO) or Y-27632 (3 µM, 
Calbiochem, Gibbstown, NJ), a specific RhoA kinase inhibitor, in the D-PBS bath along 
with perfusion of activated neutrophils in lumen. ROS generating solution composed of 
0.05 mM hypoxanthine (Hyp, Sigma, St. Louis, MO) and 0.003 U/ml xanthine oxidase 
(XO, Calbiochem, Gibbstown, NJ) was added to the vessel chamber and after a period of 
stabilization, Ang II dose response was repeated. Ang II dose response was repeated 
again in the presence of either SOD/catalase or Y-27632 along with ROS in the bath. Ang 
II dose response was also tested in the presence of TNF-α (1 ng/ml). To determine if 
ROS mediated enhanced reactivity was specific to Ang II or a non-specific phenomenon, 
norepinephrine (NE) dose response was run in 2-fold increments (0.15625 µM to 5 µM) 
and repeated in the presence of ROS generating solution. Response to Y-27632 and ROS 
was tested at a single dose of 1.25 µM NE. 
 
Western Blot 
Primary human vascular smooth muscle cells (VSMC) were isolated from 
placental chorionic plate arteries and cultured as described in Chapter 2. VSMC were 
grown to confluence in T-25 flasks in M-199 with 10% FBS. Cells were treated for 5 
minutes with Ang II alone or with Ang II plus activated neutrophils (50,000 
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neutrophils/ml) or Ang II plus ROS with and without Y-27632 (3 µM). ROS generating 
solution was composed of 0.05 mM Hyp and 0.003 U/ml XO. Western blot was 
performed for Ser19-pMLC and total MLC (Cell Signaling technologies, 1:2000, 
Beverly, MA) along with Thr696-pMYPT1 (Santa Cruz, 1:1000) and total MYPT1 (Cell 
Signaling technologies, 1:500). Blots were scanned and quantified using the Licor 
Odyssey system. β-Actin was used to normalize data. 
 
Immunokinase Assay to determine RhoA Kinase Activity  
Equal amounts of omental vessels were dissected and weighed into two 0.5 ml 
centrifuge tubes and treated with D-PBS alone (control) or D-PBS with a ROS generating 
solution composed of 0.05 mM Hyp and 0.003 U/ml XO for 5 minutes. At the end of 5 
minutes the vessels were flash frozen in liquid nitrogen and stored at -80˚C until the 
RhoA Kinase activity assay was run as described previously224. Briefly, 20 µl of Rho 
kinase immunoprecipitates were added to the reaction mixture containing 1 mM 
adenosine triphosphate (ATP) and 10 µCi of [γ-32P] ATP (3000 Ci/mol) along with 5 µg 
of myelin basic protein, followed by incubation for 15 min at 37˚C. Phosphorylation of 
myelin basic protein was absorbed onto phosphocellulose disks, and free radioactivity 
was removed by washing 3 times with 75 mM phosphoric acid (H3PO4). The amount of 
radioactivity on the disks was measured using liquid scintillation. The results are 
expressed as counts per minute per milligram protein. 
 
Data Analysis 
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The myograph experimental data were analyzed by one-way ANOVA and 
Bonferroni post-hoc test for each dose of Ang II due to significant interaction detected by 
the two-way ANOVA. The myograph experimental data for each dose of NE were 
analyzed using repeated measures two-way ANOVA with Bonferroni post-test. The 
western blot data were quantified using the average intensity measurements normalized 
to β- actin and then calculated as a percentage of the control value. The RhoA kinase 
immunoassay data were analyzed using the Mann Whitney test. A statistical software 
program was used (Prism 4, GraphPad software, San Diego, CA). All data are presented 
as mean ± SE. 
 
C. Results 
 
Effect of Neutrophils 
As shown in Figure 13, dose response to Ang II alone ranged from a 4 µ decrease 
in vessel diameter with 10-9 M Ang II up to a 14 µ decrease with 10-6 M Ang II. When 
neutrophils were perfused through the vessel lumen and Ang II dose response was 
repeated, vascular reactivity to Ang II was significantly enhanced at all doses (Fig.14). 
The vessel diameter decreased by an average of 46 µ with 10-5 M Ang II in the presence 
of activated neutrophils in the vessel lumen. Addition of SOD/Catalase to the myograph 
chamber to quench ROS significantly blocked enhanced vascular reactivity to Ang II 
(Fig.15). The specific RhoA kinase inhibitor, Y-27632, also abolished enhanced vascular 
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reactivity to Ang II in the presence of neutrophils (Fig.16). Perfusion with either IL-8 
alone or un-activated neutrophils did not affect the Ang II dose response. 
 
Effect of ROS and TNF-α 
As shown in Figure 17, addition of a ROS generating solution to the myograph 
chamber significantly enhanced vascular reactivity to Ang II similar to that seen with 
perfusion of activated neutrophils. Endothelium intact vessels also showed a significant 
increase in vessel reactivity to Ang II in the presence of ROS. However, the response was 
attenuated because of endothelial compensatory mechanisms as would be expected 
(Fig.17 B). Also similar to neutrophils, addition of SOD/Catalase (Fig.18) or Y-27632 
(Fig.19) significantly inhibited ROS induced enhancement of vascular reactivity to Ang 
II. ROS generating solution by itself caused contraction of only -2.67±1.61 µ. 
Contraction induced by ROS alone was excluded for measurement of enhanced vascular 
reactivity to Ang II. In contrast to ROS, TNF-α, another neutrophil inflammatory product 
did not alter vascular reactivity to Ang II (Fig.20, N=4, p>0.1). 
 
Effect of Neutrophils and ROS on RhoA kinase activity and expression of pMYPT1 and 
pMLC 
Human omental vessels treated with a ROS generating solution for 5 minutes 
showed a significant increase in RhoA kinase activity as compared to control (Fig.21). To 
confirm increased RhoA kinase activity, the effect of ROS and neutrophils on 
phosphorylation of MYPT1 and MLC was evaluated by Western blot in VSMC. 
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Treatment with ROS plus Ang II or neutrophils plus Ang II increased phosphorylation of 
MYPT1 which is the protein directly phosphorylated by RhoA kinase. Y-27632 inhibited 
phosphorylation of MYPT1 by ROS and neutrophils (Fig.22). As shown in Fig.23, 
treatment of VSMC with ROS or neutrophils in the presence of Ang II significantly 
increased phosphorylation of MLC, which is consistent with inhibition of myosin light 
chain phosphatase by pMYPT1. Phosphorylation of MLC was reduced by Y-27632. 
Treatment of VSMC with Ang II alone did not significantly increase phosphorylation of 
MYPT1 or MLC over control. 
 
Norepinephrine Dose Response 
As shown in Fig. 24A, ROS significantly enhanced the vasoconstrictive response 
to all doses of NE tested (N=6, p<0.001) except the 0.3125 µM dose. At 1.25 µM dose 
the increase in vasoconstrictive response to NE by ROS was significantly inhibited by 
addition of Y-27632 (Fig. 24B, N=4, p<0.05). 
 
 
D. Discussion 
In this study we demonstrate that vascular reactivity of human omental vessels to Ang II 
is markedly increased in the presence of ROS in both endothelium intact and endothelium 
denuded vessels. Enhancement of vascular reactivity was less in the presence of 
endothelium as would be expected due to endothelial compensatory factors such as nitric 
oxide and prostacyclin. Removal of the endothelium enabled the study of direct effects of 
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ROS on the vascular smooth muscle contractile apparatus without activation of 
endothelial pathways, and so was used for neutrophil experiments. Increased vessel 
reactivity to Ang II was due to ROS because co-treatment with SOD/catalase to quench 
ROS completely inhibited enhanced vessel reactivity to both ROS and neutrophils. The 
enhancement to ROS was via the RhoA kinase pathway because the enhanced response 
was abolished by using a specific RhoA kinase inhibitor. This was confirmed with ex-
vivo omental vessels treated with ROS showing increased Rho kinase activity as well as 
in cell culture experiments using human vascular smooth muscle cells which 
demonstrated increased phosphorylation of MLC and MYPT1 in the presence of ROS or 
neutrophils. The enhanced vessel responsiveness to Ang II was specific to ROS as 
another neutrophil product, TNFa, was ineffective. The ability of ROS to enhance 
vascular reactivity via the RhoA kinase pathway was not limited to Ang II as ROS also 
enhanced vascular reactivity to NE, another vasoconstrictor. NE release is induced by 
stress and sympathetic activation, factors reported to be associated with preeclampsia153-
155. Our findings of enhanced vessel reactivity to Ang II and NE in the presence of ROS 
or neutrophils may explain hypertension in pregnancy and why women who are destined 
to develop preeclampsia have an increased sensitivity to Ang II before clinical symptoms 
of hypertension are manifest123. 
Our findings may extend to hypertension in non-pregnant as well as pregnant 
subjects because RhoA kinase has been shown to play a critical role in chronic 
hypertension139, 225. Obesity is a known risk factor for chronic hypertension, as well as 
preeclampsia223, and we recently reported extensive systemic vascular infiltration of 
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neutrophils in obese women97. The vascular phenotype of the obese women was similar 
to that of preeclamptic women. Thus, vascular infiltration of neutrophils may help 
explain the relationship between obesity and hypertensive disorders, such as chronic 
hypertension and preeclampsia.  
Our recent finding of extensive vascular infiltration of neutrophils in women with 
preeclampsia95, 96 challenged conventional thinking because neutrophils are usually 
thought of as part of the innate immune system and the first line of defense against 
infection at the site of a wound53 226. A role for neutrophils in non-infectious disease has 
not been widely studied, but accumulating evidence indicates a role for neutrophils in 
“sterile” inflammatory diseases227.  
The reason neutrophils may be playing an important role in pregnancy is that in 
normal pregnancy, the number of neutrophils increases 2.5-fold by 30 weeks of gestation 
228 and this number increases further in preeclampsia 54. The human placenta produces 
oxidized lipids and secretes them into the maternal circulation 36, 38, 69, 159, 229. Oxidized 
lipids are potent activators of neutrophils 66, 68, 191. In women with preeclampsia, placental 
production of oxidized lipids is significantly higher than in women with normal 
pregnancy38. One possibility for neutrophil activation occurs as they circulate through the 
intervillous space and are directly exposed to oxidized lipids released by the placenta36, 
230, 231.  Activated neutrophils in the maternal systemic circulation adhere to the 
endothelium and could cause vascular inflammation and dysfunction by release of toxic 
compounds. Neutrophil release of matrix metalloproteinase-8 and myeloperoxidase could 
compromise vascular integrity, and that coupled with increased hydrostatic pressure as a 
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result of enhanced vascular reactivity to Ang II, could promote extravasation of proteins. 
Thus, neutrophil infiltration may contribute not only to hypertension, but also to edema 
and proteinuria in preeclampsia. 
This is the first study to show that neutrophils enhance vascular reactivity by 
activating RhoA kinase pathway and the first to show that ROS activate RhoA kinase in 
human vessels. Our findings are highly significant with respect to hypertension, as 
resistance is inversely proportional to the fourth power of the radius, so even small 
decreases in vessel diameter cause large increases in resistance. For example, in our study 
the highest dose of Ang II caused a 28% increase in resistance. In the presence of ROS or 
neutrophils, Ang II caused a 101% or 115% increase in resistance, respectively, which 
was approximately a 4 fold increase in resistance over that with Ang II alone. 
 
Perspectives 
These data are the first to show that both ROS and neutrophils enhance vessel 
contractility to Ang II and NE and provide evidence that the mechanism of ROS and 
neutrophil enhanced Ang II reactivity is by activating RhoA kinase. These data support 
the idea that neutrophil infiltration into systemic vasculature of preeclamptic women may 
be a cause of hypertension. There is no definitive treatment for preeclampsia, but these 
new data could provide novel avenues for treatment based on regulation of neutrophil 
infiltration. Potential treatments that are becoming available for clinical studies are 
neutralizing antibodies against adhesion molecules and selective RhoA kinase inhibitors. 
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Angiotensin II facilitates norepinephrine release from sympathetic nerve endings and 
prevents norepinephrine re-uptake and thus enhances sympathetic adrenergic activity. 
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Figure 13. Vessel reactivity to Ang II alone. Ang II (0.001 µM) caused a mean 
vasoconstriction of  7 µ while maximum mean vasoconstriction of 20 µ was obtained 
with 1 µM Ang II (N=20). 
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Figure 14. Vessel reactivity to Ang II in the presence of neutrophils. Perfusion of 
activated neutrophils (<2000/mm3) through the vessel lumen significantly enhanced 
vessel reactivity to Ang II. Ang II (0.001 µM) caused a mean vasoconstriction of 12 µ 
while maximum mean vasoconstriction of 50 µ was obtained with 10 µM Ang II in the 
presence of neutrophils (N=10, ** p<0.01, *** p<0.001). 
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Figure 15. Role of ROS in enhancing vessel reactivity to Ang II by neutrophils. Addition 
of SOD/catalase to quench ROS abolished enhancement of vessel reactivity to Ang II by 
neutrophils. (N= 4, ** p<0.01, *** p<0.001). 
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Figure 16. Role of RhoA kinase pathway in enhancing vessel reactivity to Ang II by 
neutrophils. Addition of Y-27632, a specific RhoA kinase inhibitor, abolished 
enhancement of vessel reactivity to Ang II by neutrophils. (N= 4, * p<0.05, ** p<0.01). 
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Figure 17. Vessel reactivity to Ang II in the presence of ROS. Addition of a ROS 
generating solution in the bath significantly enhanced vessel reactivity to Ang II, similar 
to that seen with neutrophils. A) In endothelium denuded vessels, Ang II (0.001 µM) 
caused a mean vasoconstriction of 12 µ while maximum mean vasoconstriction of 48 µ 
was obtained with 10 µM Ang II in the presence of ROS (N=17, ** p<0.01, *** 
p<0.001). B) In endothelium intact vessels, Ang II (0.001 µM) caused a mean 
vasoconstriction of 8 µ while maximum mean vasoconstriction of 25 µ was obtained with 
10 µM Ang II in the presence of ROS (N=6, * p<0.05, ** p<0.01).  
0.0001 0.001 0.01 0.1 1 10 100
-60
-50
-40
-30
-20
-10
0
Ang II
Ang II + ROS
***
**
***
AII Dose (µM)
A 
B 
 75
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 18. Specificity of ROS in enhancing vessel reactivity to Ang II. Addition of 
SOD/catalase to quench ROS abolished enhancement of vessel reactivity to Ang II. (N= 
4, * p<0.05, ** p<0.01). 
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Figure 19. Role of RhoA kinase pathway in enhancing vessel reactivity to Ang II by 
ROS. Addition of Y-27632, a specific RhoA kinase inhibitor, abolished enhancement of 
vessel reactivity to Ang II by ROS. (N= 4, * p<0.05, ** p<0.01). 
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Figure 20. Vessel reactivity to Ang II in the presence of TNF-α. Addition of 1 ng/ml of 
TNF-α in the bath did not significantly affect vessel reactivity to Ang II (0.001 µM to 10 
µM, N=17). 
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Figure 21. RhoA kinase activity in human omental vessels. RhoA kinase activity in 
omental vessels treated with ROS showed a 3-fold increase as compared to control (N=5, 
** p<0.01). 
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Figure 22. Thr-696 pMYPT1 (phosphorylated regulatory target sub-unit of myosin light 
chain phosphatase) expression in cultured human vascular smooth muscle cells. A) 
Representative Western blot of pMYPT1 and total MYPT1 normalized to β-actin in 
cultured human VSMC. B) Mean band density of pMYPT1 expression normalized to β-
actin and plotted as percentage of control. VSMC were treated with control media, Ang II 
alone, Ang II plus ROS generating solution or activated neutrophils with and without Y-
27632 (Y) for 5 min. Treatment with ROS or activated neutrophils significantly enhanced 
phosphorylation of MYPT1 which was inhibited by Y-27632 (N=3, * p<0.05). 
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Figure 23. Expression of Ser-19 pMLC (phosphorylated myosin light chain) in cultured 
human vascular smooth muscle cells. A) Representative Western blot of pMLC and total 
MLC normalized to β-actin in cultured human VSMC. B) Mean band density of pMLC 
expression normalized to β-actin and plotted as percentage of control. VSMC were 
treated with control media, Ang II alone, Ang II plus ROS generating solution or 
activated neutrophils with and without Y-27632 (Y) for 5 min. Treatment with ROS or 
activated neutrophils significantly enhanced phosphorylation of MLC which was 
inhibited by Y-27632 (N=5, * p<0.05). 
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Figure 24. Vessel reactivity to norepinephrine (NE). A) Dose response of vessel 
reactivity to NE was significantly enhanced in the presence of ROS compared to NE 
alone (N=6, ***p<0.001). B) Addition of Y-27632 (Y) abolished enhanced vessel 
reactivity to NE in response to ROS at 1.25 µM dose of NE (N=4, *p<0.05). 
B 
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Chapter 4 
 
MATRIX METALLOPROTEINASE-1 CAUSES DOSE DEPENDENT 
VASOCONSTRICTION AND ENHANCES VESSEL REACTIVITY TO 
ANGIOTENSIN II VIA PROTEASE ACTIVATED RECEPTOR-1 AND 
ENDOTHELIN-1 
 
 
A. Introduction  
Preeclampsia is a hypertensive disorder of pregnancy that complicates 5-7% of all 
pregnancies resulting in significant maternal and fetal mortality and morbidity5.  
Recently, we showed significant increase in plasma MMP-1 level and MMP-1 expression 
in the vasculature of women with preeclampsia (Estrada-Gutierrez, Walsh, unpublished). 
Consistent with a 7-fold increase in MMP-1 gene expression, pro-MMP-1 as well as 
activated MMP-1 were more abundant in omental vessels from preeclamptic women as 
compared to normal pregnant women. Immunohistochemistry showed significantly 
greater staining for MMP-1 in the endothelium, vascular smooth muscle and infiltrating 
leukocytes in subcutaneous fat blood vessels of preeclamptic women.  
Increased vascular expression of MMP-1 may be responsible for the edema and 
protein leakage in preeclampsia due to its ability to degrade type 1 collagen. However, 
MMP-1 has recently been shown to activate protease activated receptor-1 (PAR-1) also 
 83
known as thrombin receptor209, 210, 212, 213. Activation of endothelial PAR-1 results in 
release of endothelin-1 (ET-1)217, which is a potent vasoconstrictor and can enhance 
vascular reactivity to angiotensin II (Ang II)198.  
 
In this study, we tested a novel hypothesis that MMP-1 has vasoconstrictive 
properties via activation of PAR-1 and release of ET-1. To test this hypothesis we used 
human omental vessels and a pressure myograph system to record real time changes in 
vessel diameter in response to MMP-1. We also tested if MMP-1 enhances vessel 
reactivity to Ang II.  
 
B. Materials and Methods 
 
Study Subjects 
Omental fat biopsies (approximately 2 cm x 4 cm x 2 cm) were collected from 21 
normal pregnant women undergoing term C-section at MCV Hospitals, Virginia 
Commonwealth University Medical Center. Omental fat is a highly vascularized tissue 
containing resistance vessels representative of the systemic vasculature. Demographic 
data on the subjects were (Mean±SD): age (28.5±6 years), systolic blood pressure 
(126±15 mmHg), diastolic blood pressure (77±10 mmHg), gestational age (39±1 weeks), 
birth weight (3379±444 grams). Sixteen subjects were primiparous and 5 were 
multiparous. Mean lumen diameter of omental vessels studied was 281 ± 70 µ. The 
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Office of Research Subjects Protection of Virginia Commonwealth University approved 
this study and all subjects gave informed consent. IRB No. HM12361. 
 
MMP-1 Activation 
All MMPs are produced in a latent form (pro-MMP or zymogen) and require 
activation. Commercially obtained human pro-MMP-1 (Calbiochem 444208; Stock 80 
µg/ml) was activated using amino-phenyl mercuric acetate (APMA, Calbiochem 
164610). A 10 mM APMA solution was prepared by dissolving 35.18 mg APMA in 0.1 
M sodium hydroxide (NaOH). This 10 mM APMA is stable for 1 week at 4˚C. To initiate 
activation, 5 µl of pro-MMP-1 (400 ng) was diluted with 85 µl of Tris-Triton-Calcium 
(TTC) buffer and 10 µl of 10 mM APMA for a final volume of 100 µl. This was 
incubated for 2 hours at 37˚C. TTC buffer was 50 mM Tris-hydrochloride (Tris-HCl) at 
pH 7.5 with 1 mM calcium chloride (CaCl2) and 0.05% Triton X-100. For APMA 
elimination, a Microcon Centrifugal Filter Device, Ultracel YM-10 (10,000 MW), was 
blocked with 100 µl of 1 mg/ml bovine serum albumin (BSA) for 30 min at 37˚C. Then, 
after addition of 100 µl of D-PBS, it was centrifuged at 11,000 x g for 20 minutes at 4˚C. 
The filter device was then inverted onto a new tube, spun briefly and left to dry. Then, 
100 µl of MMP-1 mixture was transferred to the blocked filter device, and after adding 
200 µl of D-PBS, it was centrifuged at 11,000 x g for 20 minutes at 4˚C to wash out the 
APMA. The filtrate was discarded and this step repeated to ensure maximal removal of 
APMA. The filter device was then inverted on a new tube and spun briefly. The 
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recovered activated MMP-1 was diluted to a total volume of 100 µl to give a final 
concentration of 400 ng/100 µl. 
 
Myograph Experiments 
The omental fat biopsy was placed in Dulbecco’s phosphate buffered saline (D-
PBS, Gibco Invitrogen, Carlsbad, CA) on a silicone dissection dish pre-cooled to 4˚C. A 
1 cm length of a vessel 200-500 µ diameter was dissected and mounted on glass micro-
cannulae of a myograph system (Model 110P, Danish Myo Technologies (DMT), 
Denmark, Netherlands). For some experiments, endothelium was denuded by passing a 
fine metal wire through the vessel lumen. The vessel was immersed in 10 ml of D-PBS 
and secured at both ends using two 11-O silk suture ties at each end. The myograph 
chamber temperature was maintained at 37˚C and the vessel pressures maintained at 
constant inlet (45 mmHg) and outlet (42 mmHg) pressures to achieve flow through the 
vessel. The MMP-1 dose response was run in 10-fold increments in concentrations 0.025-
25 ng/ml in endothelium intact as well as endothelium denuded omental vessels. The 
MMP-1 dose response was repeated with perfusion of 10 µM PAR-1 inhibitor SCH-
79797 (Tocris, Ellisville, Missouri) or 5 µM ET-1 Type A receptor blocker, BQ-123 
(Sigma-Aldrich, St.Louis, Missouri). The Ang II dose response was run alone in 10-fold 
increments (0.001-10 µM) and in the presence of 2.5 ng/ml of MMP-1. The Ang II dose 
response in the presence of MMP-1 was repeated with perfusion of 10 µM SCH-79797 or 
5 µM BQ-123. 
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Data Analysis 
The myograph experiment data were analyzed by one-way ANOVA and 
Bonferroni post-test (MMP-1 dose response data) or two-way ANOVA with Bonferroni 
posttests (Ang II dose response plus MMP-1 data) using a statistical software program 
(Prism 4, GraphPad software, San Diego, CA). Data are presented as mean ± SE. 
 
C. Results 
 
MMP-1 dose response 
As shown in Figure 25, when MMP-1 was perfused through the vessel lumen in 
endothelium intact human omental vessels it caused dose dependent vasoconstriction 
ranging from an average decrease of 5 µ with 0.025 ng/ml MMP-1 to an average decrease 
of 40 µ with 25 ng/ml MMP-1. When MMP-1 was perfused through the vessel lumen in 
endothelium denuded human omental vessels, it did not cause dose dependent 
vasoconstriction.  
 
Role of PAR-1 and ET-1 in MMP-1 induced vasoconstriction 
As shown in Figure 26, co-perfusion of a PAR-1 inhibitor (10 µM SCH-79797) 
with MMP-1 in endothelium intact omental vessels abolished MMP-1 induced 
vasoconstriction. As shown in Figure 27, co-perfusion of 5 µM BQ-123, an ETA receptor 
blocker, with MMP-1 in endothelium intact omental vessels also abolished MMP-1 
induced vasoconstriction.  
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MMP-1 mediated enhancement of vascular reactivity to Ang II 
As shown in Figure 28, dose response to Ang II alone in endothelium intact 
vessels ranged from a 4 µ mean decrease in vessel diameter with 0.001 µM Ang II and up 
to a 16 µ mean decrease with 10 µM Ang II. When activated MMP-1 (2.5 ng/ml) was 
perfused through the vessel lumen and the Ang II dose response was repeated, vascular 
reactivity to Ang II at all doses (0.001 µM to 10 µM) was significantly enhanced. Vessel 
diameter decreased by an average of 10 µ with 0.001 µM Ang II and an average of 43 µ 
with 10 µM Ang II in the presence of MMP-1. Vasoconstriction to MMP-1 alone was 
excluded to calculate the change in vessel diameter induced by the Ang II dose.  
 
Role of PAR-1 and ET-1 in MMP-1 induced enhanced vascular reactivity to Angiotensin 
II 
Co-perfusion of a 10 µM SCH-79797, a specific PAR-1 inhibitor, with Ang II 
plus MMP-1 abolished MMP-1 enhanced vascular reactivity to Ang II (Fig. 29). 
Similarly, co-perfusion of 5µM BQ-123, an ETA receptor blocker, abolished enhanced 
vascular reactivity to Ang II induced by MMP-1 (Fig.30). 
 
D. Discussion 
In this study we demonstrated for the first time that MMP-1 perfusion caused 
dose-dependent vasoconstriction in endothelium intact human omental vessels and also 
enhanced vascular reactivity to Ang II. Both of these effects were abolished by co-
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perfusion with a PAR-1 inhibitor or an ETA receptor blocker. These data indicate that 
MMP-1 induced vasoconstriction and enhanced vascular reactivity to Ang II is mediated 
by PAR-1 activation leading to release of ET-1 acting on the ETA receptor. 
MMP-1 is best known as a collagenase. However, in recent years it has been 
reported to activate the thrombin receptor, PAR-1, by cleaving the N-terminal peptide 
sequence just two amino acids distal to the thrombin cleavage site209, 210, 212, 213. PAR-1 is 
expressed on the surface of endothelial cells and its activation by either MMP-1 or 
thrombin results in endothelial cell activation as evidenced by release of chymase, IL-8, 
P-selectin and ET-1 from the Weibel Palade bodies within the endothelial cells18, 217, 232. 
Thus, MMP-1 can mediate its vasoconstrictive effects by PAR-1 mediated release of ET-
1, a potent vasoconstrictor. PAR-1 activation also up-regulates expression of activated 
MMP-2233, which is known to cleave big endothelin to ET-1234. ET-1 is a vasoconstrictor 
and has been shown to enhance vascular reactivity to Ang II198 via activation of ETA 
receptors on vascular smooth muscle cells235. 
In normal pregnancy, basal levels of MMP-1 and ET-1 may have a role in 
maintaining vascular tone198. However, in preeclampsia, levels of MMP-1 and ET-1236,8 
are significantly greater than in normal pregnancy. Neutrophils can produce MMP-1218, 
thus, activated neutrophils in the maternal circulation are a potential source of elevated 
plasma levels of MMP-1 in preeclampsia. Another source of elevated plasma levels is 
release of MMP-1 by vascular smooth muscle cells resulting from release of TNF-α by 
infiltrating neutrophils237. Our recent findings of greater gene and protein expression of 
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MMP-1 in omental and subcutaneous fat vessels in preeclamptic women support a role 
for MMP-1 in the pathogenesis of preeclampsia.  
In this study, we demonstrated that the presence of activated MMP-1 in the lumen 
of resistance vessels caused dose dependent vasoconstriction and enhanced the 
vasoconstrictive response to Ang II via PAR-1 activation and ET-1. In preeclamptic 
women elevated levels of MMP-1 might explain enhanced vascular reactivity to Ang II. 
MMP-1 induced narrowing of vessels, even at normal Ang II levels, would lead to 
increased intravascular hydrostatic pressure and reduced capacity of the vascular system 
resulting in high blood pressure and a tendency towards extravasation of intravascular 
fluid leading to edema, features common to preeclampsia.  
 
E. Perspectives 
These data are the first to show that activated MMP-1 causes vasoconstriction and 
enhances vascular reactivity to Ang II. These new data could provide novel avenues for 
treatment of preeclampsia by targeting PAR-1 or ETA receptor. Potential treatments that 
are available and being used clinically for other indications are the class of ETA/B 
antagonists, like Bosentan, and SCH 530348, an orally active PAR-1 inhibitor238. 
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Figure 25. MMP-1 induced vasoconstriction: Role of endothelium. MMP-1 perfusion into 
the vessel lumen caused dose dependent vasoconstriction (0.25-25 ng/ml) in endothelium 
intact human omental vessels (N=12). MMP-1 perfusion did not induce vasoconstriction 
in the absence of endothelium (N=4). (*p<0.05, ** p<0.01, *** p<0.001) 
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Figure 26. Role of protease activated receptor-1 (PAR-1) in MMP-1 induced 
vasoconstriction. In endothelium intact human omental vessels, perfusion of 10 µM SCH-
79797, a specific PAR-1 blocker inhibited MMP-1 induced vasoconstriction (N=5, * 
p<0.05, **p<0.01, *** p<0.001). 
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Figure 27. Role of ET-1 in MMP-1 induced vasoconstriction. In endothelium intact 
human omental vessels, perfusion of 5 µM BQ-123, a specific endothelin type-A (ETA) 
receptor blocker, inhibited MMP-1 induced vasoconstriction (N=5, *p<0.05, *** 
p<0.001). 
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Figure 28. Vascular reactivity to Ang II in the presence of MMP-1 in endothelium intact 
human omental vessels. Perfusion of MMP-1 (2.5 ng/ml) through the vessel lumen 
significantly enhanced vascular reactivity to Ang II in endothelium intact human omental 
vessels at all doses of Ang II tested. (N=12, *p<0.05, ** p<0.01, *** p<0.001).  
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Figure 29. Effect of PAR-1 inhibitor on vascular reactivity to Ang II in the presence of 
MMP-1 in endothelium intact human omental vessels. Perfusion of 10 µM SCH-79797, a 
specific PAR-1 blocker, abolished MMP-1 mediated enhancement of vascular reactivity 
to Ang II. (N=4, *p<0.05, ** p<0.01). 
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Figure 30. Effect of ETA receptor blocker on vascular reactivity to Ang II in endothelium 
intact human omental vessels. Perfusion of 5 µMBQ-123, a specific ETA receptor blocker 
abolished MMP-1 mediated enhancement of vascular reactivity to Ang II. (N=4, *p<0.05, 
** p<0.01). 
       
 
 
 
Chapter 5 
 
PHOSPHATIDYL INOSITOL 3-KINASE AND INSULIN RESISTANCE IN 
PREECLAMPSIA 
 
A. Introduction 
 
Women with preeclampsia have increased incidence of insulin resistance and 
show changes similar to that of metabolic syndrome. For example, Martinez et al 
reported 73% higher fasting plasma insulin concentrations and four-fold higher post-load 
plasma insulin levels in preeclamptic women239. Kaaja et al showed the presence of 
hypertriglyceridemia, low HDL2 cholesterol and hyperuricemia in the blood of 
preeclamptic women240.  
 
Insulin Resistance  
 
i. Definition: Insulin resistance (IR) is the condition in which normal amounts of insulin 
are inadequate to produce a normal insulin response from fat, muscle and liver cells 
(en.wikipedia.org/wiki/Insulin_resistance). Compensatory increase in insulin 
production by the pancreatic β-islet cells leads to hyperinsulinemia. Hyperinsulinemia 
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protects against the rise in blood glucose levels until the compensatory ability of the 
pancreas is overwhelmed and overt diabetes mellitus (DM Type II) is manifest. Thus, 
insulin resistance is a prelude to diabetes and maybe present in the absence of glucose 
intolerance. 
  Insulin resistance                      Glucose Intolerance                      DM Type II 
 
ii. Insulin Signaling Pathway:  
Insulin rapidly stimulates glucose uptake by the muscle cells and adipocytes by 
accelerating GLUT-4 translocation. GLUT-4 transporters mediate facilitated glucose 
uptake into the cell. The rate-limiting step at which insulin stimulates glucose uptake is 
translocation of GLUT-4 transporters to the plasma membrane241. GLUT-4 translocation 
involves synthesis of specialized vesicles containing GLUT-4 transporters by the 
endosomal system, transport of these vesicles from the perinuclear region towards the 
plasma membrane, followed by fusion with the plasma membrane242.  
Phosphatidyl inositol 3-kinase (PI3K) dependent Pathway (Fig.31): The insulin 
receptor is a hetero-tetrameric membrane protein composed of two identical α and β 
chains. Insulin docking at its binding site between the two α chains results in 
autophosphorylation of the tyrosine residues within the β subunits. This recruits insulin 
receptor substrates (IRS) which bind to the activated insulin receptor via phosphotyrosine 
binding. This results in tyrosine phosphorylation of IRS by the activated insulin 
receptor243. Tyrosine phosphorylation of insulin receptor substrates recruits the regulatory 
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subunit p85 of PI3K and brings the catalytic subunit p110α close to the membrane. PI3K 
p110α  generates phosphatidyl inositol 3,4,5-triphosphate (PIP3) from phosphatidyl 
inositol (4,5)-bisphosphate. The PIP3 then activates 3’ phosphoinositide-dependent 
kinase-1 (PDK-1). Activation of PDK-1 leads to phosphorylation and activation of 
protein kinase Akt (protein kinase B) and also protein kinase C λ/ς. Wortmannin and L-
294002, PI3K inhibitors, as well as biological blockade of PI3K signaling pathway using 
dominant negative mutants inhibit insulin stimulated GLUT-4 translocation and glucose 
uptake244-247. Phosphorylation of Akt substrate 160 (AS160) by protein kinase Akt 
activates AS160.  Activation of AS160 activates the GTPase activating domain (GAP) 
for Rabs, which are small G-proteins important for vesicle formation, movement and 
fusion248. The GTPase activating domain for a Rab on AS160 is essential for GLUT-4 
translocation249. 
Khan et al hypothesized the existence of an alternative PI3K independent pathway 
for insulin mediated GLUT-4 translocation acting via changes in the cytoskeleton and 
lipid raft organization250. The contribution of this pathway, if any, would be minimal and 
the PI3K dependent pathway remains to date the most important pathway for insulin 
mediated GLUT-4 translocation. 
 
iii. Evidence of Insulin Resistance in Preeclampsia:  
Women with preeclampsia show hyperglycemic responses to both oral and 
intravenous glucose load tests251, 252. Women with pregnancy-induced hypertension have 
been shown to have higher fasting levels of insulin239, 240, 253 and increased insulin 
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response to oral glucose load as compared to the normotensive women239, 253. The higher 
insulin levels with similar glucose tolerance curves demonstrate development of insulin 
resistance. Martinez et al showed that though the glucose tolerance curves did not differ 
significantly, fasting plasma insulin concentrations were significantly higher and post-
load plasma insulin values fourfold higher in the preeclamptic group than normal 
pregnant group239. Sowers et al showed that women who subsequently developed 
preeclampsia had higher fasting plasma insulin levels at 20 weeks than control who 
maintained normotensive values252.  
Insulin resistance along with obesity characterize metabolic syndrome. One-third 
of all preeclamptic pregnancies have metabolic syndrome254. Higher serum insulin levels 
have been shown to persist for as long as 17 years after preeclamptic pregnancy255. 
Development of preeclampsia may contribute to an increased risk of cardiovascular 
diseases in later life256, 257. Obesity is a risk factor for preeclampsia and is also 
characterized by inflammation of the vasculature, insulin resistance, hypertension, 
hypertrigylceridemia, hyperlipidemia, low HDL2 and hyperuricemia240 forming a clinical 
picture of metabolic syndrome in preeclampsia.  
 
iv. Preeclampsia and Insulin Resistance: The Common Link - Inflammation?  
Inflammation of the systemic vasculature is a common feature of obesity and 
preeclampsia. Walsh and colleagues have shown the presence of increased numbers of 
activated neutrophils in the vasculature of normal weight preeclamptic women95, 96, 258 
and non-pregnant obese women97. The degree of inflammation correlates with the extent 
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of obesity. This state of chronic inflammation is associated with oxidative stress and the 
local release of cytokines like TNFα, which interferes with insulin signal transduction259, 
260 and possibly GLUT-4 translocation.  
Oxidative stress within neutrophils generates NO2+ (nitronium ion). NO2+ nitrates 
protein tyrosine residues to 3-nitrotyrosine in a reaction catalyzed by superoxide 
dismutase (SOD)261. Tyrosine nitration may have the potential to interfere with tyrosine 
phosphorylation involved in insulin signaling thus contributing to insulin resistance in 
preeclampsia. 
 
v. Role of TNF-α in development of insulin resistance:  
Studies in knock out mice of TNF-α gene, as well as its two receptors, provided 
direct evidence of TNF-α as an inhibitor of the insulin-signaling pathway262. In ob/ob 
mice and dietary induced obese mice, ablation of TNFα improved insulin sensitivity and 
prevented the obesity related insulin resistance in muscle and adipose tissue262. 
Plomgaard et al demonstrated that TNFα infusion in healthy humans induced insulin 
resistance without an effect on endogenous glucose production263. TNFα specifically 
induces insulin resistance by increasing serine phosphorylation of insulin receptor 
substrate-1 (IRS-1). This converts IRS-1 to an inhibitor of tyrosine kinase activity259, 264. 
As discussed earlier, IRS-1 plays an important role in effecting insulin mediated GLUT-4 
translocation and glucose uptake in skeletal muscle265. TNFα inhibits AS160 
phosphorylation. Phosphorylation of AS160 promotes GLUT-4 exocytosis to the plasma 
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membrane facilitating glucose uptake249, 266. Thus, TNFα inhibits GLUT-4 translocation, 
and as a result, promotes insulin resistance. 
Though there is no direct evidence showing down-regulation of PI3K in response 
to TNFα, it is likely that TNFα down-regulates the activity and or expression of PI3K as 
PI3K is the direct downstream target of tyrosine phosphorylated IRS-1 and upstream of 
pAkt, both of which have been shown to be inhibited by TNFα263. In preeclamptic 
women the levels of TNFα and its soluble receptors are significantly higher than those in 
normal pregnant women267. TNFα is a major secretory product of purified 
cytotrophoblast cells exposed to hypoxic conditions in vitro and in villous explants268. 
Walsh and Wang reported increased TNFα levels and mRNA expression in preeclamptic 
placentas69. 
In 2005, Vaughan and Walsh showed that neutrophils from normal pregnant 
women when activated by oxidative stress and linoleic acid released TNF-α 191. In 
preeclampsia, there are elevated levels of linoleic acid,269  oxidative stress230 and 
neutrophil infiltration within the systemic vasculature95, 96, 258. Thus, local release of 
TNFα by activated neutrophils270 infiltrating the systemic vasculature could mediate the 
insulin resistance seen in preeclampsia. We hypothesized that activated neutrophils and 
neutrophil products, like TNFα and ROS, will impair PI3K expression in vascular 
smooth muscle cells thus contributing to insulin resistance in preeclampsia. 
 
B. Materials and Methods 
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Placental arterial smooth muscle (PASM) cells were grown in culture and treated 
with control (medium M-199), neutrophils activated using arachidonic acid (50µM), 
TNF-α (1 ng/ml) or ROS generating solution in medium M-199, described in detail in 
Chapter 2. To quantify PI3K p85α and p110α by Western blot, PASM cells were grown 
and treated with cell treatments in T-25 flasks overnight. The media was aspirated 
followed by scraping the cells in 1 ml of ice cold sterile PBS. The cells scraped in PBS 
were centrifuged at 2000 x g at 4˚C for 5 minutes. After discarding the supernatant, 200 
µl of M-PER buffer was added and mixed well. The cell suspension with M-PER buffer 
was placed on a shaker for 10 min and then centrifuged at 14,000 x g for 20 minutes. The 
supernatant was collected and frozen to -80˚C. The pellet of cell debris was discarded. 
Protein concentration in the collected supernatant was quantified using the Pierce BCA 
Protein Assay Kit. 
To prepare 2 ml of M-PER buffer, 80 µl of protease inhibitor (PI) stock solution 
and 40 µl of 100 mM sodium orthovanadate (SOV) was added to 1.880 ml of M-PER 
(Pierce). PI stock solution was prepared by dissolving 2 Complete PI tablets (Roche) in 4 
ml of ddH2O and stored as 150 µl aliquots at -20˚C for up to 12 wks. Solution of SOV 
was prepared as 10 ml of 100 mM SOV in ddH2O in a 50 ml polypropylene tube. The pH 
was adjusted to 10.0 using 1 N hydrochloric acid (HCl) and warmed in a beaker of 
boiling water till the solution turned clear (approx 20 minutes). After the solution had 
cooled to room temperature, it was stored in 100 µl aliquots at -20˚C. For Western 
blotting, the Invitrogen Xcell Surelock system was used for electrophoresis and the 
Odyssey (Licor) system was used for scanning fluorescence tagged secondary antibodies. 
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Sample Preparation: Equal concentrations of protein per sample were calculated 
and volumized to 22.5 µl with ddH2O. To this 1.5 µl of 20X reducing agent and 6 µl of 
5X Laemli’s Buffer were added. Samples were placed in boiling water at 100˚C for 15 
minutes followed by cooling on ice and centrifugation at 4˚C for 1 minute. The samples 
were then applied to the wells of the gel using gel loading pipette tips. Biorad All Blue 
protein standards were run in the first lane of every Western blot. 
Antibodies, Electrophoresis and Transfer for PI3K p85α, p110α: Primary rabbit 
monoclonal anti-PI3K p110α antibody (Cell signaling technologies, 1:500) and anti-PI3K 
p85α antibody (Millipore, 1:1000) were used for overnight incubation at 4˚C. Primary 
mouse monoclonal anti-β actin Ig (Sigma, 1:10,000) was added to control for variable 
protein loading. Secondary antibodies, IRDye 800 anti-mouse antibody (Licor, 1:30,000) 
and AlexaFluor 680 goat anti-rabbit antibody (Invitrogen, 1:10,000) were incubated for 
45 minutes at room temperature. When stored at 4˚C, both primary and secondary 
antibody solutions could be re-used several times. 
For electrophoresis, precast 8% Novex Tris-Glycine mini-gels from Invitrogen 
were used with sample loading of 25 µg protein/well and electrophoresis was run at 125V 
for 1.5 hours. After electrophoresis, the gel was washed with ddH2O followed by 
equilibration in methanol free transfer buffer for 15-20 minutes. A 0.45 µ pore size PVDF 
membrane (Millipore) was wetted in 100% methanol for 30 seconds followed by rinsing 
in ddH2O and equilibration in methanol free transfer buffer for 15 minutes. Ice cold 
methanol free transfer buffer was used to soak the blotting pads taking care to remove all 
air bubbles. The sandwich for transfer composed of 3 blotting pads, filter paper, gel, 
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PVDF membrane, filter paper and 3 blotting pads was assembled and transfer was run for 
3 hours at 35V. Coomasie blue staining of the gel was used to confirm optimal transfer of 
protein. 
Quantification of PI3K was done using densitometric analysis by Odyssey 
software. The values were normalized to β-actin and calculated as a percentage of control 
to be compared by one-way ANOVA and the Newman Keuls post-test. 
 
C. Results 
 
i. PI3K p85α Western Blot  
As shown in Fig. 32, expression of the regulatory sub-unit of phosphatidyl inositol 3-
kinase, p85α, in primary human vascular smooth muscle cell culture was significantly 
decreased when co-cultured with activated neutrophils overnight (N=4, p<0.05).  
Similarly neutrophil products like ROS (N = 6, * p<0.05) and TNFα (N = 7, ** p<0.01) 
also significantly decreased expression of PI3K p85α. 
 
ii. PI3K p110α Western Blot  
As shown in Fig. 33, expression of the catalytic sub-unit of phosphatidyl inositol 3-
kinase, p110α, in primary human vascular smooth muscle cell culture was significantly 
decreased when co-cultured with activated neutrophils overnight (N=4, p<0.05).  
Similarly neutrophil products like ROS (N = 5, * p<0.05) and TNFα (N = 6, ** p<0.01) 
also significantly decreased expression of PI3K p110α. 
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D. Discussion 
Our data show that activated neutrophils and the neutrophil products, ROS and 
TNF-α, significantly decrease expression of the PI3K regulatory and catalytic subunits, 
p85α and p110α, respectively, in primary human vascular smooth muscle cell culture. 
The catalytic subunit of PI3K, p110α, is important for GLUT-4 mediated glucose uptake 
(Fig. 31). It is interesting to note that TNF-α inhibits insulin signaling and glucose 
metabolism in humans271, 272 but not in rodents273. This brings to light inter-species 
differences in the sensitivity to cytokines, which may be one of the reasons preeclampsia 
is a disorder unique to human pregnancy. 
 TNF-α is known to affect intracellular insulin signaling in fat, skeletal muscle 
and other insulin responsive tissues by inhibiting kinase activity in the proximal part of 
the insulin-signaling pathway260, 274, 275. TNF-α also affects a similar signaling pathway in 
vascular endothelium that results in production of nitric oxide (NO)276, which mediates 
insulin-stimulated vasodilation277-279. We show that neutrophils and ROS also affect 
insulin-signaling pathway by decreasing the regulatory (p85α) and catalytic (p110α) 
subunits of PI3K. Thus, in addition to TNF-α, neutrophils and ROS also contribute to 
insulin resistance and vascular dysfunction in preeclampsia. 
Neutrophils could be involved in maintaining a vicious cycle perpetuating insulin 
resistance by down-regulation of PI3K. TNFα release by activated neutrophils in the 
maternal circulation or within the vasculature would inhibit the PI3K/Akt pathway. 
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Inhibition of the PI3K/Akt pathway within the vascular smooth muscle cells would 
inhibit GLUT-4 translocation and thus induce insulin resistance259, 263, 264, 272.  
Although hypertension of preeclampsia falls rapidly with delivery of the placenta, 
Fuh et al reported that it took 2 months after delivery for the insulin insensitivity to 
decrease280. Jacober et al reported no difference in insulin sensitivity 3-6 months post-
partum281. With delivery of the placenta, a major source of lipid peroxides is lost, 
reducing oxidative stress. Without the placenta, there is no ongoing neutrophil activation 
and TNFα release. Eventually, new neutrophils are released from the bone marrow and 
the state of vascular inflammation can be reversed. Thus, neutrophil infiltration and 
release of TNFα could explain the reversible nature of the insulin resistance seen in 
preeclamptic women.  
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Figure 31. Phosphatidyl inositol 3-kinase (PI3K) dependent insulin mediated GLUT-4 
translocation pathway. Insulin mediated activation of insulin receptor causes tyrosine 
phosphorylation of insulin receptor substrate-1 (IRS-1) which activates the regulatory 
(p85α) and catalytic subunits (p110α) of PI3K. Activated PI3K phosphorylates its 
substrate, membrane phosphatidyl inositol 3,4,5 triphosphate, to result in phosphorylation 
of Akt and Akt substrate 160 (AS160). Activation of AS160 activates the GTPase 
activating domain (GAP) for Rabs, which are small G-proteins important for vesicle 
formation, movement and fusion248. The GTPase activating domain for Rab on AS160 is 
essential for GLUT-4 translocation. When in the plasma membrane, GLUT-4 receptors 
facilitate glucose uptake by the cells. 
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Figure 32. Expression of the regulatory sub-unit of phosphatidyl inositol 3-kinase, p85α, 
in vascular smooth muscle cell culture. Expression of p85α is significantly decreased 
with treatments of activated neutrophils (N=4, * p<0.05) or neutrophil products, ROS 
(N=6) and TNFα (N = 7,** p<0.01). 
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Figure 33. Expression of the catalytic sub-unit of phosphatidyl inositol 3-kinase, p110α, 
in vascular smooth muscle cell culture. Expression of p110α is significantly decreased 
with treatments of activated neutrophils (N=4, * p<0.05) or neutrophil products, ROS 
(N=5,* p<0.05) and TNFα (N = 6, ** p<0.01). 
       
 
 
 
CHAPTER 6 
 
 
DISCUSSION 
 
This investigation is the first to demonstrate a cause for the development of 
hypertension in preeclampsia. It goes on to explain the pathways by which neutrophils 
and neutrophil products can give rise to the pathogenesis of preeclampsia. We began by 
noting the significantly increased neutrophil infiltration and inflammation within the 
systemic vasculature of preeclamptic women96 and proposed that this neutrophil 
infiltration leads to increased vessel reactivity to Ang II, which is seen in women 
predestined to develop preeclampsia123. 
We began our investigation by testing vessel reactivity to Ang II in omental 
vessels from normal pregnant women with perfusion of activated neutrophils through the 
vessel lumen. The presence of neutrophils significantly increased vessel reactivity to Ang 
II. Increased vessel reactivity to Ang II leads to hypertension and reduced circulatory 
volume in preeclampsia.   
Activated neutrophils release a number of inflammatory mediators, such as ROS 
and TNF-α. To elucidate the mechanism by which neutrophils increase vessel reactivity 
to Ang II, we tested vessel reactivity to Ang II with perfusion of neutrophils in the 
presence of SOD/catalase to quench the ROS generated. This abolished the increased 
vessel reactivity observed with neutrophils. To confirm the role of ROS, and to exclude 
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the role of other neutrophil products like TNF-α, we repeated the Ang II dose response in 
the presence of a ROS generating solution and also with TNF-α. While ROS enhanced 
vessel reactivity to Ang II similar to that seen with neutrophil perfusion, TNF-α did not 
affect vessel reactivity to Ang II.  
A major mechanism of increasing vessel reactivity to Ang II in vascular smooth 
muscle cells is the RhoA kinase pathway. ROS can activate RhoA kinase134. Therefore, to 
determine whether ROS were activating RhoA kinase to result in enhanced vessel 
reactivity, we used Y-27632, a specific RhoA kinase inhibitor. Addition of Y-27632 
significantly reduced the increased vessel reactivity to Ang II in the presence of 
neutrophils or ROS. To confirm the role of the RhoA kinase pathway, we measured 
RhoA kinase activity using a previously validated assay in omental vessels treated with 
ROS224. Omental vessels exposed to ROS showed a 3-fold increase in RhoA kinase 
activity as compared to control vessel segments. 
We also quantified expression levels of Thr-696 pMYPT1 and Ser-19 pMLC in 
vascular smooth muscle cell culture treated with Ang II plus ROS or neutrophils, with 
and without Y-27632. Both ROS and neutrophils significantly increased expression 
levels of pMYPT1 and pMLC in the absence of Y-27632, but not in the presence of Y-
27632. Thus, we conclude that neutrophil release of ROS activates RhoA kinase to 
increase vessel reactivity to Ang II.  
To determine if ROS activation of RhoA kinase could affect vessel reactivity to 
other vasoconstrictors, we tested NE in the presence of ROS, with or without Y-27632. 
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We found that ROS activation of RhoA kinase also enhanced vessel reactivity to NE, so 
ROS enhancement of vessel reactivity appears to be a generalized mechanism. 
In light of the recent findings of increased expression of MMP-1 within the 
systemic vasculature of preeclamptic women with increased MMP-1 gene expression in 
omental vessels and increased plasma levels of MMP-1 in preeclamptic women (Estrada-
Gutierrez, unpublished), we proposed a role of MMP-1 in the pathogenesis of 
preeclampsia. We found that MMP-1 caused direct dose-dependent vasoconstriction and 
enhanced vessel reactivity to Ang II in endothelium intact vessels. Both effects were 
mediated via PAR-1 endothelial activation and release of ET-1.  
Women with preeclampsia also have insulin resistance240. To determine whether 
neutrophils or neutrophil products could play a role in the development of insulin 
resistance, we quantified protein expression levels of the regulatory (p85α) and catalytic 
(p110α) subunits of PI3K in vascular smooth muscle cell culture with treatments of 
activated neutrophils, ROS, TNF-α and control. Neutrophils, ROS and TNF-α 
significantly decreased expression of the catalytic subunit (p110α) of PI3K. Neutrophils 
and TNF-α also significantly decreased expression of the regulatory subunit (p85α) of 
PI3K. PI3K plays a pivotal role in insulin-mediated GLUT-4 translocation to the plasma 
membrane244, 247, so a neutrophil mediated decrease in PI3K would interfere with cellular 
glucose uptake. Decreased glucose uptake by cells is a hallmark of insulin resistance.  
Our results demonstrate that neutrophils and neutrophil products act as the 
common denominator in the pathogenesis of preeclampsia contributing to increased 
vessel reactivity and vasoconstriction leading to hypertension along with insulin 
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resistance forming a clinical picture of preeclampsia (Fig.35). Our recent finding of 
extensive vascular infiltration of neutrophils in women with preeclampsia95, 96 challenged 
conventional thinking because neutrophils are usually thought of as part of the innate 
immune system and the first line of defense against infection at the site of a wound53 226. 
A role for neutrophils in a non-infectious disease, like preeclampsia, has not been widely 
studied. However, accumulating evidence indicates a role for neutrophils in “sterile” 
inflammatory diseases227. The reason neutrophils may be playing an important role in 
pregnancy is that in normal pregnancy, the number of neutrophils increases 2.5-fold by 
30 weeks of gestation 228 and this number increases further in preeclampsia 54. The 
human placenta produces oxidized lipids and secretes them into the maternal circulation 
36, 38, 69, 159, 229. Oxidized lipids are potent activators of neutrophils 66, 68, 191. In women with 
preeclampsia, placental production of oxidized lipids is significantly higher than in 
women with normal pregnancy38. One possibility for neutrophil activation occurs as they 
circulate through the intervillous space and are directly exposed to oxidized lipids 
released by the placenta36, 230, 231.  Activated neutrophils in the maternal systemic 
circulation adhere to the endothelium and could cause vascular inflammation and 
dysfunction by release of toxic compounds. Neutrophil release of matrix 
metalloproteinase-8 and myeloperoxidase could compromise vascular integrity. 
 
Neutrophils also express and produce MMP-1218. Moreover, our lab has shown 
that neutrophil and neutrophil products stimulate VSMC to produce MMP-1 and IL-8 
(Estrada-Gutierrez, Walsh, unpublished). IL-8 being a chemo attractant to neutrophils 
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will attract more neutrophils into the vasculature forming a self-perpetuating cycle of on-
going neutrophil infiltration leading to increasing production of MMP-1 contributing to 
increasing vasoconstriction and worsening of hypertension. Constant production of 
MMP-1 by VSMC under the influence of neutrophils could be another mechanism to 
explain the increased vessel reactivity to Ang II. The vascular effects of MMP-1 were 
mediated via PAR-1. PAR-1 expression is significantly increased in preeclamptic 
omental vessels as compared to normal pregnant women; and in VSMC neutrophils, ROS 
and TNF-α significantly increase PAR-1 expression (Estrada-Gutierrez, Walsh, 
unpublished). Thus, the effects of MMP-1 would likely be magnified many fold in 
preeclamptic women with both endothelial and VSMC expressing PAR-1. One of the 
limitations of the present study is that vessels from preeclamptic women were not 
evaluated. It would be interesting to repeat these experiments in vessels from 
preeclamptic women and evaluate the role of PAR-1 mediated direct intracellular calcium 
entry into VSMC as future studies. Also, MMP-1 is a collagenase, like MMP-8 
(neutrophil collagenase), and could compromise vascular integrity which when coupled 
with increased hydrostatic pressure as a result of enhanced vascular reactivity to Ang II, 
would lead to extravasation of protein. Thus, neutrophil infiltration and increased MMP-1 
may be contributing not only to hypertension, but also to the edema and proteinuria seen 
in preeclampsia. 
Apart from vasoconstriction and increased vascular reactivity leading to 
hypertension in preeclampsia, neutrophils and neutrophil products also inhibited VSMC 
expression of regulatory and catalytic subunits of PI3K which could explain insulin 
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resistance in preeclampsia. These studies were done in VSMC culture and future studies 
for PI3K activity in preeclamptic vessels compared to normal are warranted. Moreover, it 
would be interesting to do real time polymerase chain reaction for quantifying gene 
expression along with epigenetic studies to determine if neutrophils or neutrophil 
products lead to epigenetic alteration of the PI3K genes. 
In conclusion, neutrophils may be playing a key central role in the pathogenesis of 
preeclampsia (Fig. 34). Neutrophil products like ROS and MMP-1 can increase vessel 
reactivity to cause hypertension, while ROS and TNF-α inhibit PI3K to cause insulin 
resistance. Moreover, MMP-1 can also cause direct vasoconstriction and compromise 
vascular integrity that could lead to edema and proteinuria. 
The work presented in this thesis offers several options for development of 
preventive and therapeutic treatments for preeclampsia. For example, use of neutrophil 
neutralizing antibodies and antibodies against adhesion molecules could prevent 
neutrophil infiltration of the systemic vasculature and thus prevent development of 
clinical manifestations of preeclampsia, or even reverse signs of preeclampsia by 
preventing new neutrophil infiltration. RhoA kinase inhibitors could be studied to 
determine their ability to control blood pressure in preeclampsia by blocking 
enhancement of vessel reactivity to Ang II and NE. MMP-1 neutralizing antibodies could 
possibly impair the ability of MMP-1 to induce vasoconstriction, enhance vessel 
reactivity and compromise vascular integrity, thus potentially reducing blood pressure 
and reversing edema and proteinuria. Since the vasoconstrictive properties of MMP-1 are 
mediated via PAR-1 and ET-1 release, PAR-1 inhibitors and ETA receptor blockers 
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would be excellent drug development targets to pursue for blood pressure control in 
preeclampsia. Intracellular pharmacologic stimulators of PI3K could be developed and 
studied as potential drugs to regain insulin sensitivity. This could also find application in 
the treatment of obesity associated metabolic syndrome and Type II DM, in addition to 
the treatment of preeclampsia. Thus, the work presented in this thesis has multiple 
applications and serves to better understand the complex pathogenesis of preeclampsia, a 
leading cause of maternal and neonatal mortality and morbidity. 
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Figure 34. Neutrophils: The common denominator in the pathogenesis of preeclampsia. 
Vascular infiltration of neutrophils leads to production of reactive oxygen species that 
lead to increased vessel reactivity and insulin resistance. Neutrophil release of MMP-1 or 
stimulation of vascular MMP-1 leads to vasoconstriction, increased vessel reactivity and 
compromised vascular integrity leading to hypertension, edema and proteinuria. On the 
other hand, TNF-α, another neutrophil product, contributes to insulin resistance without 
affecting vessel reactivity. Thus, vascular infiltration of neutrophils could explain the 
development of hypertension, insulin resistance, edema and proteinuria in preeclampsia. 
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